Engineered microbial cells producing a dopamine precursor for use in treating neurologal diseases

Engineered microbial cells secreting L-DOPA in the GI tract address the instability of dopamine delivery in Parkinson's Disease, achieving stable dopamine levels and reducing toxicity, thus effectively treating the disease.

WO2026234106A1PCT designated stage Publication Date: 2026-11-12SNIPR BIOME APS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063120
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for neurological diseases like Parkinson's Disease, such as L-DOPA therapy, suffer from side effects like L-DOPA induced dyskinesia due to pulsated dopamine delivery, and there is a lack of effective methods to stabilize and maintain brain dopamine levels.

Method used

Engineered microbial cells, such as bacteria, are administered to the gastrointestinal tract to secrete L-DOPA, which is metabolized to dopamine, providing stable and elevated brain dopamine levels, reducing 3-OMD-mediated toxicity, and stabilizing DOPAC levels.

Benefits of technology

The method achieves elevated and stabilized brain dopamine levels, reducing dopamine fluctuations and 3-OMD toxicity, thereby effectively treating or preventing neurological diseases with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063120_12112026_PF_FP_ABST
    Figure EP2026063120_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a medicament for GI tract administration that comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine, for use in a method for treating or preventing a neurological disease or condition or a symptom thereof Of interest are such cells which secrete L-3,4-dihydroxyphenylalanine (L-DOPA). In aspects, the invention provides such means and methods for elevating brain dopamine, maintaining elevated brain dopamine and / or stabilizing elevated brain dopamine. In aspects, the invention provides such means and methods for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level in a method for treating or preventing a neurological disease or condition or a symptom thereof. In aspects, the invention provides such means and methods for elevating brain dopamine and reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity for treating or preventing a neurological disease or condition or a symptom thereof.
Need to check novelty before this filing date? Find Prior Art

Description

MEDICAMENTS, COMPOSITIONS & METHODSFIELD OF THE INVENTION

[0001] The invention relates to a medicament for GI tract administration that comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine, for use in a method for treating or preventing a neurological disease or condition or a symptom thereof. Of interest are such cells which secrete L-3,4-dihydroxyphenylalanine (L-DOPA). In aspects, the invention provides such means and methods for elevating brain dopamine, maintaining elevated brain dopamine and / or stabilizing elevated brain dopamine. In aspects, the invention provides such means and methods for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level in a method for treating or preventing a neurological disease or condition or a symptom thereof. In aspects, the invention provides such means and methods for elevating brain dopamine and reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity for treating or preventing a neurological disease or condition or a symptom thereof.BACKGROUND OF THE INVENTION

[0002] Levodopa (L-DOPA), an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-a-amino-b-(3,4-dihydroxybenzene)propanoic acid. Its empirical formula is C9H11NO4, and its structural formula iso

[0003] Current evidence indicates that symptoms of Parkinson’s Disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson’s Disease apparently because it does not cross the blood-brain barrier. L-DOPA is able to cross the protective blood-brain barrier and enter the brain, where it is further converted into dopamine by the enzyme DOPA decarboxylase (DDC). Because L-DOPA can be converted into dopamine within the peripheral nervous systems, which may contribute to L-DOPA -related adverse side effects, L-DOPA is conventionally given in combination with a peripheral DDC inhibitor, such as carbidopa or benserazide to prevent its breakdown in the bloodstream, so more L-DOPA can enter the brain.

[0004] More than 10 million people worldwide, and one million Americans have Parkinson’s Disease (PD), and approximately 50,000 new cases are diagnosed each year, with the incidence among aging population exceeding that for other younger segments of the US population. In addition, Parkinsonian disorders including progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) have overlapping neurological deficits and clinical pathology with PD. The cardinal pathology of PD is progressive neurodegeneration of dopamine-producing neurons in substantia nigra, contributing to dopamine deficiency that manifest in severe motor symptoms including rigidity, bradykinesia, tremors, and postural instability. The amino acid L-DOPA is the precursor to the neurotransmitter dopamine, and has been used for the treatment of a variety of neurological disorders including PD. The discovery of dopamine replacement therapy with Levodopa (L-DOPA) for PD represents one of the most remarkable success stories in the history of medicine. For decades, L-DOPA is the drug most often prescribed because it's unparalleled symptomatic relief to PD patients. Unfortunately, L-DOPA gold standard therapy met inherent side effects commonly referred to L-DOPA induced dyskinesia (LID). Although neurochemical basis of LID is not completely understood, dopamine receptor sensitization due to pulsated delivery of L-DOPA in form of 100-500 mg tablet 2 times day is considered to be major reason for the LID. The clinical diagnosis of L-DOPA drug fluctuations include peak dose, off period dystonia, and diphasic dyskinesia. In the face of antiparkinsonian treatment, the lack of effective treatment to control LID remains by far the most challenging problem.

[0005] EP0287341Bldiscloses rectally absorbable form of L-DOPA.

[0006] US11576883B2 and US20220031771A1 disclose engineered microbial cells that produce L-DOPA that are said therein to be useful for treating PD. Effect on plasma dopamine levels is studied. These do not provide any data on the aspects demonstrated in the present disclosure showing elevated, stabilised and maintained brain dopamine; lower 3-OMD, and elevated DOPAC.BRIEF SUMMARY OF THE INVENTION

[0007] Therefore, it is an object of the present invention to provide medicaments, methods and compositions to deliver L-DOPA for production of dopamine in an elevated and stable manner in the brain. This may thereby avoid pulsated delivery and the L-DOPA induced dyskinesia associated with the standard treatment regimen. Other objects will become apparent from the description of the invention which follows.

[0008] In a First Configuration, the invention provides:A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting adopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)), for use in a method for treating or preventing a neurological disease or condition or a symptom thereof in the subject.A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)), for use in a method for treating or preventing a symptom of a neurological disease or condition in the subject.A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)), for use in a method for treating or preventing a neurological disease or condition in the subject.

[0009] Preferred aspects provide :- A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered bacterial cells that are capable of secreting L-DOPA, for use in a method for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0010] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating brain dopamine for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0011] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain dopamine for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0012] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain dopamine for treating or preventing a neurological disease or condition or a symptom thereof in the subject, whereinthe brain dopoamine is elevated at least 2-fold in the brain in a period of at least 24 hours, wherein said period is immediately post administration of the medicament.

[0013] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for maintaining elevated brain dopamine in the subject whilst reducing the risk of dopamine fluctuation for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0014] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for maintaining elevated brain dopamine in the subject whilst reducing the risk of dopamine fluctuation for at least 5 consecutive hours in a period of 24 hours, wherein said period is immediately post administration of the medicament, for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0015] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level and treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0016] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level and treating or preventing a neurological disease or condition or a symptom thereof in the subject, wherein the DOPAC is elevated at least 2-fold in the brain in a period of 24 hours, wherein said period is immediately post administration of the medicament.

[0017] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity in the subject and treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0018] A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating brain dopamine and reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity in the subject for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

[0019] The invention also provides :- A pharmaceutical composition comprising engineered microbial cells as defined in any preceding method of the invention, and a pharmaceutically acceptable excipient or carrier.A method for treating or preventing a neurological disease or condition in a subject, the method comprising administering to the GI tract of the subject a medicament or composition according the invention.BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The figures show the following.Figure 1. Schematic representation of the constructed L-DOPA producing cells: L-tyrosine is transported into the cell through transporters like tyrP. L-tyrosine is converted into L-DOPA by the enzymatic action of 4-hydroxyphenylacetate 3 -hydroxylase encoded by hpaBC located on a plasmid in the cell. The intracellular level of tyrosine available for conversion into L-DOPA is increased by deleting tyrR from the chromosome, thereby increasing expression of tyrP, as well as tyrA and tyrB leading to more chorismate being converted into L-tyrosine.Figure 2. Schematic representation of the study design. The study started on day 1, showing the timing and route of treatment and sampling. The G-number in each of the sampling timepoints indicate a certain group sampled. On day 7 (day of termination) blood were sampled at all timepoints indicated, whereas brain and feces were samples at timepoints encased in a black box indicating termination of the animals (schematics by CRO).Figure 3. Schematic of the study design. On day 0 the animals were given the 6-OHDA brain lesion on one side of the brain and were given 7 days for recovery. On day 7 the osmotic pump was surgically placed in all animals and dosing initiated hereafter. For 6 days the animals were dosed twice daily and on day 14 (7 days of treatment) the animals were dosed once followed by akinesia tests before termination.Figure 4. L-DOPA production in strains carrying the hpaBC operon. L-DOPA production was determined by a colorimetric assay in two biological replicates for each strain. L-DOPA concentration was also determined in culture supernatants by LC-MS (numbers above columns in pM). Strain b7591 serves as a non-producing control. The presence of the tyrosine repressor (TyrR), the locationof the hpaBC operon (chromosomal - chr or plasmid - p), and the promoter transcribing the hpaBC operon (medium strength - Pm or strong - Ps) is indicated for each strain.Figure 5. Quantification of b9375 in feces of all rats in the study. Results show that only groups 2-5 had colonization of b9375 in feces and that selection for the plasmid (Strep+Chl) indicated same level as selection for the bacteria itself (Strep) indicating stability of the plasmid after 7 days of daily dosing.Figure 6. . L-dopa, dopamine, 3-OMD and DOPAC levels in blood (ng / mL) on day 1 after the first dose. The white dot with grey outline indicated the baseline, with the black showing values for E. coli (b9375) dosed animals and grey for L-dopa dosed animals.Figure 7. L-dopa, dopamine, 3-OMD and DOPAC levels in blood (ng / mL) on day 8 at termination. The white dot with grey outline indicated the baseline, with the black showing values for E. coli (b9375) dosed animals and grey for L-dopa dosed animals.Figure 8. L-dopa, dopamine, 3-OMD and DOPAC levels in brain (ng / mL) at termination after the last dose on day 7. The white dot with grey outline indicated the baseline, with the black showing values for E. coli (b9375) dosed animals and grey for L-dopa dosed animals.Figure 9. Quantification of b9375 in feces of all rats in the study. Results showed that colonization of b9375 in feces and that selection for the plasmid (Strep+Chl) indicated same level as selection for the bacteria itself (Strep) indicating stability of the plasmid after 7 days of daily dosing.Figure 10. The initiation test showed the time (seconds) taken for a rat to use it’s right front paw (affected paw). Each rat is represented by a black dot. The time noted is between 1 and 90 seconds, with no initiation before 90 seconds would be noted as 90 seconds.Figure 11. The cylinder test looked at the total time the rat used it’s right paw (affected / sick), left paw (compensating) and both paws simultaneously. Each animal is represented by a black dot. The healthy control animals use their right and left paw approximately 28% of the time each, and both paws at 44% of the time, whereas the disease control animals decrease the time using the right paw and compensatingly increases the use of the left paw. The L-dopa control shows a somewhat normalization as the treatment control.DETAILED DESCRIPTION OF THE INVENTIONDefinitions

[0021] In the disclosure herein, the following terminology will be used in accordance with the definitions set out below.

[0022] The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and / or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used to mean "and / or" unless explicitly indicated to refer to alternatives only or the alternatives are mutuallyexclusive, although the disclosure supports a definition that refers to only alternatives and "and / or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

[0023] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0024] The term "or combinations thereof or similar as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0025] Numeric ranges recited within the specification, including ranges of “greater than,” “at least”, or “less than” a numeric value, are inclusive of the numbers defining the range and include each integer within the defined range. For example, when a range of “1 to 5” is recited, the recited range should be construed as including ranges “1 to 4”, “1 to 3”, “1-2”, “1-2 & 4-5”, “1-3 & 5”, and the like.

[0026] The term “about” as used herein, refers to variation in the numerical quantity that can occur, for example, through typical measuring techniques and equipment, with respect to any quantifiable variable, including, but not limited to, mass, volume, time, distance, wave length, frequency, voltage, current, and electromagnetic field. Further, given solid and liquid handling procedures used in the real world, there is certain inadvertent error and variation that is likely through differences in the manufacture, source, or purity of the ingredients used to make the compositions or carry out the methods and the like. The term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. The term “about” also encompasses these variations. Whether or not modified by the term “about,” the claims include equivalents to the quantities.

[0027] ‘Probiotic” is used to refer to live, non-pathogenic microorganisms, e.g., bacteria, which can confer health benefits to a host organism that contains an appropriate amount of the microorganism.

[0028] ‘Gut” refers to the organs, glands, tracts, and systems that are responsible for the transfer and digestion of food, absorption of nutrients, and excretion of waste. In humans, the gut iscomprised by the gastrointestinal tract, which starts at the mouth and ends at the anus. The gut comprises the esophagus, stomach, small intestine, and large intestine. The gut also comprises accessory organs and glands, such as the spleen, liver, gallbladder, and pancreas. The upper gastrointestinal tract comprises the esophagus, stomach, and duodenum of the small intestine. The lower gastrointestinal tract comprises the remainder of the small intestine, i.e., thejejunum and ileum, and all of the large intestine, i.e., the cecum, colon, rectum, and anal canal. Bacteria can be found throughout the gut, e.g., in the gastrointestinal tract, and particularly in the intestines.

[0029] As used herein “recombinant” or “engineered” includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid or that the cell is derived from a cell so modified. Thus, for example, recombinant or engineered cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under-expressed or not expressed at all as a result of deliberate human intervention. The term “recombinant” as used herein does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation / transduction / transposition) such as those occurring without deliberate human intervention.

[0030] As used herein, the term “treating” means ameliorating, improving or remedying a disease, disorder, or symptom of a disease or condition. For example, with respect to Parkinson’s Disease, treatment may be measured by quantitatively or qualitatively to determine the presence / absence of the disease, or its progression or regression using, for example, symptoms associated with the disease or clinical indications associated with the pathology.

[0031] As used herein, the term “subject”, “individual”, or “patient” refers to any human or animal organism upon which embodiments of the invention may be used or administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. In some embodiments, a subject is a mammal, e.g., a human or non-human primate (e.g., an ape, monkey, orangutan, or chimpanzee), a dog, cat, guinea pig, rabbit, rat, mouse, horse, cattle, or cow.

[0032] As used herein a “pharmaceutical composition” refers to a preparation of microbial cells of the invention with other components such as a pharmaceutically acceptable carrier and / or excipient.

[0033] As used herein, the term “pharmaceutically acceptable carrier” refers to any carrier, diluent, excipient, wetting agent, buffering agent, suspending agent, lubricating agent, adjuvant, vehicle, delivery system, emulsifier, disintegrant, absorbent, preservative, surfactant, colorant, flavorant, or sweetener, preferably non-toxic, that would be suitable for use in a pharmaceutical composition. The compositions of the present invention may be administered in the form of a pharmaceutical composition with a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may be chosen to permit oral administration or administration by any other known route.

[0034] The term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples include, but are not limited to, calcium bicarbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols, and surfactants, including, for example, polysorbate 20.

[0035] As used herein, the terms “pharmaceutically effective” or “therapeutically effective” shall mean an amount of a composition that is sufficient to show a meaningful patient benefit, i.e., treatment, prevention, amelioration, or a decrease in the frequency of the condition or symptom being treated.

[0036] The invention relates to a medicament that comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine, for use in a method for treating or preventing a neurological disease or condition or a symptom thereof. Of interest are such cells which secrete L-3,4-dihydroxyphenylalanine (L-DOPA). The invention provides such means and methods for elevating brain dopamine, maintaining elevated brain dopamine and / or stabilizing elevated brain dopamine. The invention also provides such means and methods for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level in a method for treating or preventing a neurological disease or condition or a symptom thereof. The invention also provides such means and methods for elevating brain dopamine and reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity for treating or preventing a neurological disease or condition or a symptom thereof.

[0037] The following surprising activities were achieved with dosing of engineered bacteria to the GI tract, as shown in the Examples below: - • elevating brain dopamine that is useful for treating or preventing PD;• elevating and stabilizing brain dopamine level;• elevating brain dopamine whilst reducing dopamine fluctuation;• elevating and stabilizing brain DOPAC;• reducing the reduced risk of 3-OMD-mediated toxicity.And as per the worked Examples below, for durations indicative that the medicaments, compositions and methods are thereapeutically or prophylactically useful :- • elevating and stabilizing brain dopamine level more than 2-fold in the brain in the period of 24 hours immediately post administration;• elevating brain dopamine whilst reducing dopamine fluctuation for more than 5 consecutive hours in the 24 hours;• elevating and stabilizing brain DOPAC more than 2-fold in the brain in the 24 hours;

[0038] Thus, there is provided: - A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)) , for use in a method for treating or preventing a neurological disease or condition or a symptom thereof in the subject.A medicament for administration to the intestine of a subject, wherein the medicament comprises engineered bacterial cells that are capable of secreting a L-DOPA, for use in a method for treating or preventing a neurological disease or condition or a symptom thereof in the subject.A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)), for use in a method for treating or preventing a symptom of a neurological disease or condition (eg, dyskinesia) in the subject.A medicament for administration to the intestine of a subject, wherein the medicament comprises engineered bacterial cells that are capable of secreting a L-DOPA, for use in a method for treating or preventing a symptom of a neurological disease or condition (eg, dyskinesia) in the subject.

[0039] The gastrointestinal system includes the mouth, pharynx (throat), esophagus, stomach, small intestine, large intestine, rectum, and anus. Preferably, the medicament is administered orally to the intestine of the subject. Administration may be to the small intestine. Administration may be to the large intestine.

[0040] Preferably, the cells are bacterial cells. For example, the cells are bacterial cells that secrete L-DOPA.

[0041] A precursor of L-DOPA is precursor that is metabolised to L-DOPA in the GI tract (eg, in the gut), eg, in the small intestine or in the colon). L-DOPA 2-hydroxypropyl ester is a prodrug of L-DOPA, a drug used to treat Parkinson’s Disease. The 2-hydroxypropyl ester modification enhances the solubility and absorption of L-DOPA, potentially leading to a more rapid and consistent effect. The "HC" version refers to the hydrochloride salt of the ester. Optionally, the precursor is L-DOPA 2-hydroxypropyl ester, eg, L-DOPA 2-hydroxypropyl ester HC. L-DOPA is made in the body by the addition of an OH group to L-tyrosine. In an example, the cells secrete tyrosine. In an example, the cells have been engineered to metabolise tyrosine to L-DOPA. In an example, the cells have been engineered to enhance uptake by the cells of tyrosine. In an example, the cells have been engineered to enhance metabolism by the cells of tyrosine to L-DOPA.

[0042] The disease may be a Parkinsonian Disease, eg, Parkinson’s Disease (PD). Parkinsonian Disorders are a group of movement disorders characterized by similar symptoms to Parkinson’s Disease, including slow movement, stiffness, tremor, and balance problems. While Parkinson’s Disease is the most common type of parkinsonism, other conditions can also cause these symptoms

[0043] In an embodiment, the symptom is treated. In an embodiment, the progression of the symptom is reduced. In an embodiment, the risk of developing the symptom is reduced.

[0044] The disease may be selected from Parkinson’s Disease, progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).

[0045] The symptom may be selected from slow movement, stiffness, tremor, and balance problems of the subject. Preferably, the symptom is dyskinesia. Optionally, the symptom is a Parkinson’s Disease symptom. Optionally, the symptom is selected from dyskinesia, akinesia, a neurotoxicity symptom, impaired motor function (eg, impaired vestibulum function or motor coordination); olfactory dysfunction; spatial learning deficit; depression; anxiety; or a neuropsychiatric disorder.

[0046] In an embodiment, the medicament is for elevating brain dopamine in the subject for treating or preventing the neurological disease, condition or symptom. The elevation may be to a level of brain dopamine that is at least 10, 20, 30, 40, 50, 60, 70, 80 or 90% higher compared to a control subject. The elevation may be to a level of brain dopamine that is at least 2, 3, 4, 5, 67, 8, 9 or lOx (eg, 2-5, 2-4 or 2-3x; preferably at least 2x or from 2-5 x) higher compared to a control subject. The elevated dopamine preferably does not increase 3-OMD-mediated side effects compared with a control subject. In an embodiment, the control subject is a subject that has not received the medicament. In an embodiment, the control subject is a subject that has received L-DOPA treatment, such as SOC L-DOPA treatment.

[0047] In an embodiment, the medicament is for use in a method of elevating and stabilizing brain dopamine level in the subject for treating or preventing the neurological disease, condition or symptom in the subject, optionally wherein the brain dopoamine is elevated at least 2-fold in the brain in a period of at least 24 hours (ie, some time during the 24hr period said elevation occurs), wherein said period is immediately post administration of the medicament. For example, the brain dopoamine is elevated at least 2, 3, 4, 5, 67, 8, 9, 10 or 20x (eg, 2-5, 2-4 or 2-3x; preferably at least 2x or from 2-5x) in the brain in a period of at least 24 hours, wherein said period is immediately post administration of the medicament. Whilst there may be small and insignificant fluctuation in brain dopamine in a subject that has been administered the medicament, the fluctuations in said period are less than for a control subject that has not received the medicament, such that the method of the invention stabilizes the brain dopamine. For example, with the method in said period the difference between the highest level of brain dopamine is no more than 1.5-3 (eg, 1.5-2) times the lowest level. In an embodiment (as demonstrated in the working examples), the brain dopamine is stable from 5 to 20 hours after commencement of said period, eg, from 5 to 24 hours after commencement.

[0048] In an embodiment, the medicament is for use in a method of maintaining elevated brain dopamine in the subject whilst reducing the risk of dopamine fluctuation (optionally for at least 5, 6, 7, 8, 9, 10, 11 (eg, 10) consecutive hours in a period of 24 hours, wherein said period is immediately post administration of the medicament) for treating or preventing the neurological disease, condition or symptom in the subject. Optionally, the brain dopamine is elevated throughout the 6thto 24thhour of said period. Optionally, the brain dopamine is elevated throughout the 6thto 12thhour of said period. Optionally, the brain dopamine is elevated throughout the 12th to 24thhour of said period.

[0049] The concept of “elevated” is relative to the level at the time of administration of the medicament.

[0050] DOPAC is just a biomarker of dopamine function and indicative of desirable dopamine metabolism. There are indications that the levels of DOPAC are lower in PD and that increased levels are beneficial. As exemplified by working examples below, we observed DOPAC at 50 ng / ml at 4.5 hours, then 122 ng / ml at 6hrs, and 189 ng / ml at 7.5hrs. Optionally, the medicament is for use in a method for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level and treating or preventing the neurological disease, condition or symptom in the subject, optionally wherein the DOPAC level is elevated at least 2-fold (eg, at least 3, 4, 5, 67, 8, 9, 10 or 20x; eg, 2-5, 2-4 or 2-3x; preferably at least 2x or from 2-5x) in the brain in a period of 24 hours, wherein said period is immediately post administration of the medicament.

[0051] Optionally, the medicament is for reducing the reduced risk of or preventing 3-O-methyldopa (3-OMD)-mediated toxicity in the subject and treating or preventing the neurological disease, condition or symptom. Optionally, the medicament is for reducing the reduced risk of 3-O-methyldopa (3-OMD)-mediated toxicity in the subject whilst treating or preventing the neurological disease or condition or symptom. Optionally, the medicament is for reducing reducing 3-OMD to reduce a L-DOPA treatment-mediated side effect in the subject. The toxicity may be indicated by, or the side effect may be, dyskinesia.

[0052] The medicament may be for reducing the risk of or treating impaired locomotor activity, dyskinesia, neuronal damage or downregulation of brain dopamine transporter activity.

[0053] The treating may be for reducing the progression of the disease or condition or symptom.

[0054] The medicament may be fora) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain L-DOPA over said period;b) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain 3-OMD over said period;c) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain L-DOPA over said period;d) lowering the risk of an L-DOPA brain treatment side effect in the subject; e) lowering the risk of a brain dopamine fluctuation side effect in the subject; f) lowering the risk of dyskinesia, akinesia and / or a neurotoxicity symptom in the subject;g) reducing progression of dyskinesia, akinesia and / or a neurotoxicity symptom in the subject;h) improving motor function in the subject;i) reducing deterioration of motor function in the subject;j) lowering the risk of 3-OMD driven reduced L-DOPA uptake into the brain; k) lowering the risk of metabolism in the brain of L-DOPA to 3-OMD;l) treatingor reducing the risk of addiction behaviour in a subject that has previously received L-DOPA treatment (eg, L-DOPA SOC); orm) treating or preventing a neurological disease or condition whilst reducing one or more side effects (eg, dyskinesia) compared to administration of oral administration of L- DOPA per se.A “low” level is in comparison to the level in a control subject (as defined above).A “L-DOPA brain treatment side effect" may be 3-OMD mediated toxicity; or -OMD mediated reduction in L-DOPA uptake by the brain.

[0055] Dyskenesia herein may be L-DOPA induced dyskinesia (LID). Akinesia herein may be L-DOPA induced akinesia.

[0056] As observed in the working examples below, we achieved brain DOPA at below LLOQ (Lower Limit of Quantification) at all timepoints, wherein LLOQ is at 10 ng / ml. Thus, in an embodiment, the method is for treating or preventing a neurological disease or condition whilst maintaining the level of brain L-DOPA over said period below LLOQ in a standard L-DOPA in vitro assay. In an embodiment, the method is for treating or preventing a neurological disease or condition or a symptom thereof whilst maintaining the level of brain L-DOPA over said period below the L-DOPA level in a control subject (eg, a human) that has been administered oral L-DOPA but not said medicament of the invention. In an embodiment, the method is for treating or preventing a neurological disease or condition or symptom thereof whilst maintaining the level of brain L-DOPA over said period below 10 ng / ml in a standard L-DOPA in vitro assay.

[0057] In an embodiment, the method is for treating or preventing a neurological disease, condition or symptom whilst maintaining brain L-DOPA level over said period below the brain level in a subject that has received standard of care L-DOPA treatment but has not received the medicament of the invention.

[0058] For example, standard of care L-DOPA treatment as mentioned herein hcompises administration to a human subject of L-DOPA at 400-1000mg per day, eg, 700mg per day. Themedicament of any preceding claim, wherein the method comprises increasing (optionally producing to increase) a gut DOPA decarboxylase inhibitor (eg, carbidopa or benzeraside) in the subject.

[0059] Optionally, the method comprises administering the medicament and a DOPA decarboxylase inhibitor to the gut of the subject.

[0060] Optionally, the method comprises administering the medicament and a MAO-B or COMT inhibitor to the gut of the subject. MAO-B inhibitors, like selegiline and rasagiline, increase the availability of dopamine in the brain by reducing its breakdown by the enzyme MAO-B. They can be used as first-line therapy in early Parkinson’s Disease, as well as add-on therapy in later stages. Some studies suggest they may offer better motor control and quality of life than COMT inhibitors, possibly due to disease-modifying effects in addition to symptom relief. While generally well-tolerated, potential side effects include nausea, constipation, and dry mouth. They can also interact with other medications, especially those that affect serotonin levels, such as antidepressants. COMT inhibitors, like entacapone and opicapone, work by preventing the breakdown of dopamine in the peripheral tissues, thereby extending the duration and effectiveness of levodopa. They are often used in conjunction with levodopa to manage motor fluctuations and improve the "wearing-off effect. Potential side effects include nausea, diarrhea, and hallucinations. Some may also exacerbate levodopa-related dyskinesias. In an example, the MAO-B inhibitor is selected from rasagiline, selegiline and safmamide. In an example, the COMT inhibitor is selected from entacapone, opicapone and tolcapone.

[0061] Optionally, the method comprises (i) administering the medicament to the gut of the subject on a first day (Di) and (ii) in a window starting with Di and ending on the sixth day (De) thereafter administering a DOPA decarboxylase inhibitor to the GI tract of the subject on at least 3 eg, 3, 4, 5 or 6) days.

[0062] Optionally, (i) the method comprises administering said decarboxylase inhibitor on at least 4, 5 or 6 days in said window; or on each day in said window; or continuously for at least 3, 4, 5, 6 or 7 consecutive days in said window; or continuously for the 7 consecutive days of said window; or (ii) the inhibitor is administered at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg / kg or more per day (optionally from 0.5 to 15 mg / kg) of administration of the inhibitor or at 0.5mg / kg or more per day (optionally from 0.5 to 15 mg / kg) each day of said window. In standard of care (SOC) the human dose of benserazide or carbidopa is from 12.5 mg x 4 per day (which is less than 1 mg / kg) up to 200 mg x 3 per day (is approximately 10 mg / kg) in a 60 kg person. Thus, in an embodiment, said inhibitor (eg, benserazide or carbidopa) is administered to the subject in a daily amount of from 0.8 to 15 mg / kg, eg, from 1 to 10 mg / kg.

[0063] Optionally, the method comprises administering tyrosine to the subject.

[0064] Optionally, the microbial cells have been engineered to de-repress one or more tyrosine importers and / or importers of a precursor that is metabolized to tyrosine.

[0065] Optionally, the method is for reducing the risk in the subject ofa) impaired locomotor activity (eg, vestibulomotor function or motor coordination); b) neurodegeneration (eg, dopaminergic neurodegeneration in the mid-brain);c) intraneuronal inclusions;d) loss of dopaminergic neurons (eg, in the in the substantia nigra);e) olfactory dysfunction;f) spatial learning deficit;g) depression;h) anxiety;i) a neuropsychiatric disorder;j) developing one or more Parkinson’s Disease neurological symptom; and / or k) progression of one or more symptoms (eg, neurological symptoms) of Parkinson’s Disease.A symptom may be rigidity, bradykinesia, tremors or postural instability.

[0066] Optionally, the method is for reducing the risk in the subject of dyskinesia, optionally for reducing the risk of 3-O-methyldopa (3-OMD)-mediated dyskinesia in the subject.

[0067] Optionally, the condition is a neurodegenerative condition, optionally Parkinson’s Disease or Alzheimer’s Disease.

[0068] The administered microbial cells preferably reside in the gut (eg, intestine) of the subject. The microbial cells may be capable of colonizing the gut (eg, the small intestine and / or colon) of the subject. The microbial cells may grow in the gut of the subject.

[0069] The microbial cells may comprise heterologous hpaBC genes. “Heterologous” means that the genes are not naturally-occurring in the cells or strain of cells, eg, the genes have been introduced into the genome of the cells or a predecessor by genetic engineering, as the skilled addressee will understand.

[0070] The microbial cells may be devoid of a functional tyrR gene, optionally wherein (i) the microbial cells comprise a knock-out of tyrR; or (ii) the microbial cells comprise a knock-out of tyrR and knock-in of hpaBC genes. The microbial cells may be devoid of a TyrR (tyrosine repressor). The microbial cells may comprise de-repressed TyrP and / or AroP tyrosine transporters. The microbial cells may comprise de-repressed tyrosine synthesis genes tyrA and tyrB. The microbial cells may comprise heterologous nucleotide sequence encoding 4-hydroxyphenylacetate 3-hydroxylase. This sequence is optionally on a plasmid of the cells. This sequence is optionally on a chromosome of the cells. This sequence is optionally under the control of a strong promoter, eg, a strong constitutive promoter. For example, the promoter comprises a TTGACA -35 box (ie, is a strong promoter). The sequence may comprise a hpaBC operon (and optionally the cells have aknock-out of tyrR). The microbial cells may comprise hpaBC genes that are under the control of a strong promoter. In an alternative, a promoter herein is an inducible promoter.

[0071] Optionally in the method at least one dose (eg, 2, 3 or 4 doses) of the medicament is orally administered to the subject, optionally daily or weekly. Optionally in the method 2, 3 or 4 doses of the medicament are orally administered to the subject daily. The doses may be equal doses.

[0072] Each dose may comprise at least 107CFU (eg, 107to 1013CFU, 108to 1012CFU, 108to 1011CFU or 108to IO10CFU; eg, about 107, 108, 109, IO10, 1011, 1012or 1013CFU) of said microbial cells.

[0073] Optionally, in the method at least one dose of a decarboxylase inhibitor (eg, carbidopa or benzeraside) is administered to the subject (eg, daily or weekly), optionally wherein the medicament and inhibitor are co-administered to the subject. In an example a decarboxylase inhibitor is co-administered with each said dose of the medicament.

[0074] Benserazide is marketed under the brand names Madopar® in the UK and Prolopa® in Canada. Carbidopa is sold under the brand name Eodosyn®.

[0075] There is provided:- A pharmaceutical composition comprising engineered microbial cells as defined herein, and a pharmaceutically acceptable excipient or carrier.

[0076] The pharmaceutical composition may be formulated for oral or rectal administration, preferably oral administration, for example comprised by a capsule or coated tablet, a gel for retention in the GI tract (eg, in the intestine), or a suppository for rectal administration. The pharmaceutical composition may be a lyophilised formulation or is an encapsulated formulation to be released in the gut of a subject, for example in the small intestine or large intestine of a subject. The pharmaceutical composition may be formulated as an enteric late release capsule. The pharmaceutical composition may comprise (or comprises approximately) 1 x 107colony forming units (CFU) / gram (eg, 107to 1013CFU, 108to 1012CFU, 108to 1011CFU or 108to 1010CFU per gram; eg, about 107, 108, 109, 1010, 1011, 1012or 1013CFU per gram) of the engineered microbial cells.

[0077] There is provided:- A method for treating or preventing a neurological disease or condition in a subject, the method comprising administering to the GI tract of the subject a medicament or composition as described herein. This method may further comprise the features of any other method disclosed herein.

[0078] There is provided:- A medicament, composition, engineered microbial cells (eg, bacteria) or method as herein described.Microencapsulated compositions

[0079] Microencapsulated compositions comprising microbial cells (preferably bacteria) are dislosed and the medicaments described herein may comprise such compositions. The microcapsules may include a core component comprising the microbial cell and a coating materialsurrounding the core component. Optionally, the core component further comprises an aromatic amino acid- or DOPA -decarboxylase inhibitor such as carbidopa or benserazide. Optionally, the coating material comprises a polymer. In another embodiment, the coating material comprises alginic acid or an alginate.

[0080] In another embodiment, the composition is lyophilized and may further comprise a cryoprotectant. In yet another embodiment, the composition further comprises a pharmaceutically acceptable carrier.

[0081] The disclosure provides a method for treating Parkinson’s Disease in a subject (preferably a human), the method comprising administering to the subject an effective amount of a composition comprising a microbial cell or medicament described herein capable of producing L-DOPA or a precursor for production of L-DOPA in the subject. The disclosure provides a method for treating Parkinson’s Disease in a subject (eg, a human), the method comprising administering to the subject an effective amount of a medicament described herein capable of producing L-DOPA or a precursor for production of L-DOPA in the subject. In another embodiment, methods of treating Alzheimer's disease, depression and / or anxiety, memory deficits, and improving motivation to do difficult tasks are provided. The method comprises administering to the subject in need thereof an effective amount of the medicament or composition.

[0082] In a preferred embodiment, the administration is oral administration. In a preferred embodiment, the administration is rectal administration. Optionally, the composition is administered on alternate days. In certain embodiments, the subject is a mammal. In a preferred embodiment, the mammal is a human.

[0083] The microbial cell(s) preferably is capable of colonising the GI tract (eg, the gut) of the subject. The cell(s) may advantageously provide L-DOPA in a sustained manner to the brain of the subject to reduce the risk of the development of Levodopa-induced dyskinesia (LID).Microbial Cells

[0084] As the context allows, reference herein to a microbial cell and its features may instead be read as applying to a plurality of microbial cells.

[0085] The cell(s) may be constructed from any suitable host microbial cell. The host cell may be an unmodified cell or may already be genetically modified. In one embodiment, the microbial cell(s) of the composition or medicament is a gut-colonising microbial cell. The cell(s) may a prokaryotic cell(s) or a eukaryotic cell. In one embodiment, the cell is a prokaryotic cell. Preferably, each cell is a bacterial cell. The cell(s) may be an archaeal cell.

[0086] In one embodiment, the microbial cell is a nonpathogenic bacterial cell. In one embodiment, the microbial cells are nonpathogenic bacterial cells. Optionally, the microbial cell(s) is a commensal bacterial cell. Optionally, the microbial cell(s) is a yeast cell. Optionally, the microbialcell(s) is a naturally pathogenic microbial cell that is modified or mutated to reduce or eliminate pathogenicity.

[0087] The microbial cell(s) may be a probiotic cell. Some species, strains, and / or subtypes of non-pathogenic microorganisms are currently recognized as probiotic.

[0088] Examples of suitable bacterial cell species are: Bifidobacteria, Escherichia coli, Lactobacillus, and Saccharomyces. e.g., Bifidobacterium bifidum, Enterococcus faecium, Escherichia coli strain Nissle 1917, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus paracasei, Lactobacillus plantarum, and Saccharomyces boulardii.

[0089] Examples of bacteria, eg, probiotic bacteria, include Lactobacillus, Bifidobacterium, Lactococcus, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, or Escherichia coli.

[0090] Optionally, a Lactobacillus may include, without limitation, a Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus casei (such as Lactobacilluscasei Shirota), Lactobacillus salivarius, Lactobacillus paracasei, Lactobacillus lactis, Lactobacillus acidophilus, Lactobacillus sakei, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus garvieae, Lactobacillus acetotolerans, Lactobacillus agilis, Lactobacillus algidus, Lactobacillus alimentarius, Lactobacillus amylolyticus, Lactobacillus amylophilus, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus aviarus, Lactobacillus bifermentans, Lactobacillus bulgaricus, Lactobacillus carnis, Lactobacillus caternaformis, Lactobacillus cellobiosis, Lactobacillus collinoides, Lactobacillus confuses, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus divergens, Lactobacillus farciminis, Lactobacillus fructivorans, Lactobacillus fructosus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus graminis, Lactobacillus haiotoierans, Lactobacillus hamster, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus homohiochii, Lactobacillus iners, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus johnsonii, Lactobacillus kandleri, Lactobacillus kefiri, Lactobacillus kefuranofaciens, Lactobacillus kefirgranum, Lactobacillus kunkeei, Lactobacillus leichmannii, Lactobacillus llndnerl, Lactobacillus malefermentans, Lactobacillus mall, Lactobacillus maltaromicus, Lactobacillus manihotivorans, Lactobacillus minor, Lactobacillus minutus, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus nagelii, Lactobacillus oris, Lactobacillus panis, Lactobacillus parabuchneri, Lactobacillus paracasei, Lactobacillus parakefiri, Lactobacillus paralimentarius, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus perolens, Lactobacillus piscicola, Lactobacillus plantarum, Lactobacillus pontis, Lactobacillus rhamnosus, Lactobacillus rhamnosus GG, Lactobacillus rimae, Lactobacillus rogosae, Lactobacillus ruminis, Lactobacillus sanfranciscensis, Lactobacillus sharpeae, Lactobacillus suebicus, Lactobacillus trichodes, Lactobacillus uli, Lactobacillus vaccinostercus, Lactobacillus vaginalis,Lactobacillus viridescens, Lactobacillus vitulinus, Lactobacillus xylosus, Lactobacillus yamanashiensis, or a Lactobacillus zeae.

[0091] Optionally, Escherichia coli may be E. coli Nissle 1917. As used herein, the term “Escherichia” refers to a genus of Gram-negative, non-spore forming, facultatively anaerobic, rodshaped bacteria from the family Enterobacteriaceae. The genus Escherichia include various species, such as Escherichia coli. The terms “ Escherichia coli Nissle 1917” or “EcN” as used herein refer to a non-pathogenic Gram -negative probiotic bacteria Escherichia coli strain that is capable of colonizing the human gut. In an exemplary embodiment, the probiotic is the Escherichia coli strain Nissle 1917.

[0092] Escherichia coli Nissle 1917 has evolved into one of the best characterized probiotics. The strain is characterized by its complete harmlessness, and has GRAS (generally recognized as safe) status. E. coli strain Nissle 1917 lacks defined virulence factors such as alphahemolysin, other toxins, and mannose-resistant hemagglutinating adhesins, P-fimbrial adhesins, and the semi-rough lipopolysaccharide phenotype and expresses fitness factors such as microcins, ferritins, six different iron uptake systems, adhesins, and proteases, which support its survival and successful colonization of the human gut. As early as in 1917, E. coli Nissle was packaged into medicinal capsules, called MUTAFLOR®, for therapeutic use. E. coli Nissle has since been used to treat ulcerative colitis in humans in vivo, to treat inflammatory bowel disease, Crohn's disease, and pouchitis in humans in vivo, and to inhibit enteroinvasive Salmonella, Legionella, Yersinia, and Shigella in vitro. It is commonly accepted that E. coli Nissle's therapeutic efficacy and safety have convincingly been proven.

[0093] Examples of Escherichia coli Nissle 1917 bacteria include those available as DSM 6601 from the German Collection for Microorganisms in Braunschweig, Germany or commercially as the active component in MUTAFLOR© (Ardeypharm GmbH, Herdecke, Germany).

[0094] Optionally, a Bifidobacterium may be Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium animalis subsp animalis, Bifidobacterium longum, Bifidobacterium fidobacterium breve, Bifidobacterium bifidum, Bifidobacteriumanimalis subsp. lactis or Bifidobacterium lactis, such as Bifidobacterium lactis DN-173 010.

[0095] Optionally, a Bacillus may be Bacillus coagulans. Optionally, a Lactococcus may be Lactococcus lactis subsp. Lactis such as Lactococcus lactis subsp. lactis CV56. Optionally, a probiotic Enterococcus may be Enterococcus durans. Optionally, a Streptococcus maybe Streptococcus thermophilus.

[0096] Optionally, the bacterium may be an auxotrophic strain designed, for example, to limit its survival outside of the human or animal intestine, using standard techniques.

[0097] The probiotic may be a variant or a mutant strain of bacterium. Non-pathogenic bacteria may be genetically engineered to enhance or improve desired biological properties, e.g., survivability. Non-pathogenic bacteria may be genetically engineered to provide probiotic properties.Probiotic cells may be genetically engineered to enhance or improve probiotic properties, e.g., enhance gut colonization.

[0098] Bacterial strains can be readily obtained using standard methods known in the art. For example, a commensal bacterium such as Escherichia coli Nissle 1917 can be obtained from a commercial preparation of the probiotic MUTAFLOR®. Bacteria can be cultured using standard methods known in the art.

[0099] A preferred cell is an E col cell. A preferred cell is an Enterococcus (eg, E fecalis) cell. Enterococcus faecalis is a Gram -positive commensal bacterium common in the gastrointestinal tract of animals — from insects to humans, E faecalis is also one of the first colonizers of the infant GI tract. Thus, use of Enterococcus cells may be desirable in the medicament for GI tract administration and possibly colonisation of the gut of the subject.

[0100] One of ordinary skill in the art would appreciate that the genetic modifications disclosed herein may be modified and adapted for other species, strains, and subtypes of bacteria or other microorganisms.

[0101] The microbial cell may preferably be capable of producing L-DOPA and colonizing the gut of a subject. Optionally, the recombinant cell comprises heterologous nucleic acid sequences encoding 4-hydroxyphenylacetate 3 -monooxygenase (hpaB) and its FAD reductase (hpaC) for the biosynthesis of L-DOPA from L-tyrosine.

[0102] Optionally, each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1 and / or each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3.

[0103] Optionally, each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1,

[0104] Optionally, each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3.

[0105] Optionally, each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1 and each engineered cell comprises a nucleotide sequence that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3.

[0106] Optionally, the genome of each cell (eg, a chromosome or a plasmid of the cell) comprises SEQ ID NO: 1.

[0107] Optionally, the genome of each cell (eg, a chromosome or a plasmid of the cell) comprises SEQ ID NO: 3.

[0108] Optionally, the genome of each cell (eg, a chromosome or a plasmid of the cell) comprises SEQ ID NO: 1 and 3.

[0109] Additionally, other hpaB and hpaC nucleic acid sequences may be identified through databases such as Genbank. The hpaB and hpaC nucleotide sequence may be contained in a plasmid of the microbial cell. The hpaB and hpaC nucleotide sequence may be stably integrated into a chromosome of the microbial cell.

[0110] The hpaBC nucleotide sequence may be operably linked to a promoter sequence, preferably a strong promoter. Optionally, the promoter is a constitutive promoter. Optionally, the promoter is an inducible promoter. Inducible promoters allow the transcription to be turned on and modulated by the addition of an inducer. Optionally, the inducer may be administered with the composition or medicament. Optionally, the composition or medicament is preincubated with the inducer prior to administration. The inducer can be metabolites such as a sugar or environmental conditions such as hypoxia, temperature, or pH. In an exemplary embodiment, the promoter is a rhamnose-inducible promoter. Since it is a non-metabolizable inert sugar, rhamnose may be used clinically. In an embodiment, the rhamnose-inducible promoter is the rhaB promoter of the E. coli rhaBAD operon.

[0111] In one aspect, there is used EcN cells transformed with one or more plasmids expressing hpaB and hpaC for the recombinant production of L-DOPA.

[0112] Sequence identity can be determined according to sequence alignment methods known in the art. Examples of these methods include computational methods such as those that make use of the BLAST algorithm, available online from the National Center for Biotechnology Information. Sequence identity is most preferably assessed by the algorithm of BLAST version 2.1 advanced search. BLAST is a series of programs that are available, for example, online from the National Institutes of Health. References to BLAST searches are: Altschul, S. L., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) “Basic local alignment search tool.” J. Mol. Biol.215:403410; Gish, W. & States, D. J. (1993) “Identification of protein coding regions by database similarity search.” Nature Genet. 3:266272; Madden, T. L., Tatusov, R. L. & Zhang, J. (1996) “Applications of network BLAST server” Meth. Enzymol. 266: 131 141; Altschul, S. L., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997) “Gapped BLAST and PSI_BLAST: a new generation of protein database search programs.” Nucleic Acids Res.25:33893402; Zhang, J. & Madden, T. L. (1997) “PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation.” Genome Res. 7:649656.

[0113] Percent sequence identity or homology between two sequences is determined by comparing a position in the first sequence with a corresponding position in the second sequence. When the compared positions are occupied by the same nucleotide or amino acid, as the case may be, the two sequences are conserved at that position. The degree of conservation between two sequences is often expressed as a percentage representing the ratio of the number of matching positions in the two sequences to the total number of positions compared. Two nucleic acid, or two polypeptide sequences are substantially homologous to each other when the sequences exhibit at least about 70%-75%, preferably 80%-82%, more preferably 85%-90%, even more preferably 92%, still morepreferably 95%, and most preferably 98% sequence identity over a defined length of the molecules, as determined using the methods above.

[0114] Nucleic acid hybridization may also be used to identify substantially similar nucleic acid molecules to those reported herein. The present nucleic acid molecules described herein may be used to identify genes encoding substantially similar polypeptides / proteins expected to have similar function. Nucleic acid hybridization may be conducted under stringent conditions.Substantially similar sequences are defined by their ability to hybridize, under the following stringent conditions (O.lxSSC, 0.1% SDS, 65° C. and washed with 2xSSC, 0.1% SDS followed by O.lxSSC, 0.1% SDS, 65° C.).Microencapsulation

[0115] The microbial cell(s) may be microencapsulated. Microencapsulation of the microbial cell(s) can protect against low pH, a high bile-salt concentration, and high temperatures.

[0116] The microcapsules may be of any size or shape. Basic geometrical shapes may be, for example, spheres, rods, cylinders, cubes, cuboids, prism, pyramids, cones, truncated cones and truncated pyramids. The microcapsules may be of regular shape or may have be irregular in shape. The surface of the microcapsule may be smooth, uneven, or jagged.

[0117] They may be amorphous, spherical, or acicular in shape, depending on the respective method of production. In a single dosage that includes microcapsules, the microcapsules may be of uniform size and shape, or may be of variables sizes and shapes.

[0118] The microcapsules may be of any size. For example, the maximum diameter of the microcapsule may be about 10 nm, 100 nm, 1 pm, 10 pm, 50 pm, 100 pm, 200 pm, 300 pm, 400 pm, 500 pm, 600 pm, 700 pm, 800 pm, 900 pm, 1 mm, 1.5 mm, 2.0 mm, 2.5 mm, 3.0 mm, 3.5 mm, 4.0 mm, 4.5 mm, 5.0 mm, 5.5 mm, 6.0 mm, 6.5 mm, 7.0 mm, 7.5 mm, 8.0 mm, 8.5 mm, 9.0 mm, 9.5 mm, 1.0 cm or greater, or any range of maximum diameters derivable within the aforementioned maximum diameters. For example, the maximum diameter of the microcapsule may range from about 10 nm to about 1.0 cm. Optionally, the mean diameter ranges from about 100 pm to about 1 mm. Optionally, the mean diameter ranges from about 100 pm to about 0.1 mm.

[0119] The microcapsule may comprise at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or more of the microbial cells by weight.

[0120] The microcapsules may be formed using any method known to those of ordinary skill in the art. Methods for preparing microcapsules are discussed in the following U.S. Patent Application Pub. Nos.: 20080022965, 20080193653, 20070138673; 20070082829; 20060234053, 20060121122, 20050113282, 20040121155, 20040074089, and 20020009473, and the following U.S. Pat. Nos. 7,576,903, 7,037,582, 6,936,644, 6,653,256, 6,592,916, 6,486,099, 4,460,722, each of which is herein specifically incorporated by reference.

[0121] The core as used herein refers to that portion of the microcapsule that includes the microbial cell, where the microbial cell is encased in a coating material. The coating material may comprise a crosslinked nanopolymer. Some examples of coating materials include cellulose acetate pthalate, methyl acrylate -methacrylic acid copolymers, cellulose acetate succinate, hydroxy propyl methyl cellulose phthalate, hydroxy propyl methyl cellulose acetate succinate, polyvinyl acetate phthalate, methyl methacrylate-methacrylic acid copolymers, alginates, and stearic acid. The coating may include suitable hydrophilic gelling polymers including but not limited to cellulosic polymers, such as methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, and the like; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl alcohol, polyanhydride, and the like; acrylic polymers and copolymers, such as acrylic acid polymer, methacrylic acid copolymers, ethyl acrylate -methyl methacrylate copolymers, natural and synthetic gums, such as guar gum, arabic gum, xanthan gum, gelatin, collagen, proteins, polysaccharides, such as pectin, pectic acid, alginic acid, alginates, polyaminoacids, polyalcohols, polyglycols; and the like; and mixtures thereof. Any other coating material known to those of ordinary skill in the art is contemplated for inclusion in the coatings of the microcapsules set forth herein. In an exemplary embodiment, the coating material comprises alginic acid or an alginate.

[0122] The core may include one or more additional components other than the microbial cells. For example, the core may include a DOPA decarboxylase inhibitor. In certain embodiments, the decarboxylase enzyme inhibitor is carbidopa, a carbidopa prodrug, benserazide, methylphenidate, or a combination thereof.Formulations and Methods of Use

[0123] Herein are provided a composition or a medicament comprising a composition, wherein the composition comprises said microbial cells. The composition may be a microencapsulated composition and / or a lyophilized composition.

[0124] Methods of treating diseases or conditions (herein also referred to as “disorders”) associated with dopamine are contemplated; or for treating or preventing a symptom of such a disorder. The most common disease characterized by a dopamine production deficiency is Parkinson’s Disease; however, alternatively the method may be for the treatment of other diseases characterized by insufficiency of dopamine production. In one embodiment of the invention, a method of treating a disorder resulting from dopamine -related dysfunction is provided.

[0125] In one embodiment, the method of the invention is intended for treating, preventing, managing and / or delaying the progression of the disease or condition or a symptom thereof.

[0126] Examples of a suitable disease or condition are Parkinson’s Disease, restless leg syndrome, depression, stress, obesity, chronic posttraumatic stress disorder, anxiety disorders,obsessive-compulsive disorders, postpartum depression; schizophrenia, narcolepsy, manic, bipolar, and affective disorder; executive function disorders, such as attention deficit disorder (ADHD), learning and memory disorders, Tourette syndrome and autism; cocaine, amphetamine, alcohol dependency, and addictive behavior, such as pathological gambling.

[0127] Pharmaceutical compositions and medicaments comprising microbial cells can be formulated to be suitable for oral administration, for example as discrete dosage forms, such as, but not limited to, tablets (including without limitation scored or coated tablets), pills, caplets, capsules, chewable tablets, powder packets, cachets, troches, wafers, aerosol sprays, or liquids, such as but not limited to, syrups, elixirs, solutions or suspensions in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil emulsion. Suitably, the composition or medicament may be formulated in a gel for administration to the GI tract (and preferably to aid retention of the formulation in the tract, such as in the intestine of the subject).

[0128] Such compositions usually contain a predetermined amount of the disclosed cells, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams, and Wilkins, Philadelphia, Pa. (2005).

[0129] Instead of the oral dosing, noted above, the compositions of the present invention may be administered by any other suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The composition or medicament or dose may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable carrier. In an embodiment of the invention, the composition, medicament or dose may be administered intrarectally. A rectal administration preferably takes place in the form of a suppository, enema, or foam.

[0130] In certain embodiments, the compositions or medicament may be lyophilized. Lyophilization is an effective and convenient technique for preparing stable compositions that allow delivery of the cells. In some cases, the lyophilized composition is reconstituted prior to administration. In some cases, the reconstitution is by use of a diluent. Generally, at least one cryoprotectant is added to effectively lyophilize the composition. The cryoprotectants include, but are not limited to, mannitol, glycerol, dextrose, sucrose, and / or trehalose.

[0131] Optionally, the methods described herein comprise administering an effective amount of compositions or medicaments described herein to the subject in order to treat or prevent a symptom of said disease or condition. As compared with an equivalent untreated control, the symptom may be reduces by at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more as measured by any standard technique.

[0132] In certain embodiments, a dose of a composition or medicament disclosed herein can be administered to the subject once. In certain embodiments, a dose of a composition ormedicament disclosed herein can be administered to the subject once repeatedly. Optionally, the administration can be a daily administration, for example oral administration, of, e.g., a capsule comprising cells as described herein. For example, a dose of the medicament may be administered 2, 3, 4, 5 or 6 (preferably 3 or 4, eg, 3, eg, 4) times a day.

[0133] Optionally, each dose (or doses over a day) of the composition or medicament comprises from 106CFU to about 1013CFU of the microbial cells. Therefore, Optionally, each dose (or doses) is about 106, about 107, about 108, about 109, about IO10, about 1011, about 1012, or about 1013CFU. In some preferred embodiments, the dose (or doses) is 107to 109CFU. Optionally, the administration results in peak plasma levels similar to that of the standard of care U-DOPA treatment. In some embodiments, the method achieves stable therapeutic plasma U-DOPA concentrations of from about 300 to about 1600 ng / ml over time with the medicament as compared to traditional U-DOPA. Therefore, Optionally, the method achieves stable therapeutic plasma U-DOPA concentrations of about 300 ng / ml, about 400 ng / ml, about 500 ng / ml, about 600 ng / ml, about 700 ng / ml, about 800 ng / ml, about 900 ng / ml, about 1000 ng / ml, about 1100 ng / ml, about 1200 ng / ml, about 1300 ng / ml, about 1400 ng / ml, about 1500 ng / ml, about 1600 ng / ml, or more. In some preferred embodiments, the method results in peak plasma levels reaching about 1500 ng / ml. The preferred, optimal dose of the medicament maximizes gut colonisation without inducing toxicity, including gut tissue damage, inflammation or gut microbial dysbiosis.

[0134] The composition or medicament comprising microbial cells can be administered over a period of time, such as over a 5 minute, 10 minute, 15 minute, 20 minute, or 25 minute period. The administration can be repeated, for example, on a regular basis, such as hourly for 3 hours, 6 hours, 12 hours, daily (i.e. one a day), every other day (i.e. on alternate days), or longer or such as once a week, or biweekly (i.e., every two weeks) for one month, two months, three months, four months or longer. Administration may be for at least 5, 6 or 7 days.

[0135] Doses may be administered over a period of time, e.g., at appropriate intervals through a day or other appropriate schedule. Optionally, administration can be chronic, e.g., one or more doses and / or treatments daily over a period of weeks or months. Examples of dosing is daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, or more.

[0136] A pharmaceutical composition described herein may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. A composition may be formulated such that a unit dose of the composition contains a specified number of engineered microbial cells.

[0137] The methods described herein can further comprise administering a second treatment to the subject, e.g. as part of a combinatorial therapy. In certain embodiments of the present invention, the microbial cells can be used in combination therapy with at least one other therapeutic agent (eg, benzeraside or carbidopa).

[0138] In certain embodiments, the pharmaceutical compositions, and methods for the treatment further comprise administration to the subject of one or more therapeutic agents for treating Parkinson’s Disease selected from a dopaminergic agent, such as Levodopa-carbidopa (SINEMET®, SINEMET CR®) or Levodopa-benserazide (PROLOPA®, MADOPAR®, MADOPARHBS®) (eg, at lower dose than SOC, in view of the efficacy of the medicament of the invention); a dopaminergic and anti-cholinergic agent, such as amantadine (SYMMETRYL®, SYMADINE®); an anticholinergic agent, such as trihexyphenidyl (ARTANE®), benztropine (COGENTIN®), ethoproprazine (PARSITAN®), or procyclidine (KEMADRIN®); a dopamine agonist, such as apomorphine, bromocriptine (PARLODEL®), cabergoline (DOSTINEX®), lisuride (DOPERGINE®), pergolide (PERMAX®), pramipexole (MIRAPEX®), or ropinirole (REQUIP®); a MAO-B (monoamine oxidase B) inhibitor, such as selegiline or deprenyl (ATAPRYL®, CARBEX®, ELDEPRYL®); a COMT (catechol O-methyltransferase) inhibitor, such as CGP-28014, tolcapone (TASMAR®) or entacapone (COMTAN®); or other therapeutic agents, such as baclofen (LIORESAL®), domperidone (MOTILIUM®), fludrocortisone (FLORINEF®), midodrine (AMATINE®), oxybutynin (DITROPAN®), propranolol (INDERAL®, INDERAL-LA®), clonazepam (RIVOTRIL®), or yohimbine.

[0139] The other therapeutic agent can be an anti-depression agent. Useful antidepression agents include, but are not limited to, amitriptyline, clomipramine, doxepine, imipramine, triripramine, amoxapine, desipramine, maprotiline, nortriptyline, protripyline, fluoxetine, fluvoxamine, paroxetine, setraline, venlafaxine, bupropion, nefazodone, trazodone, phenelzine, tranylcypromine and selegiline. The anti -depression agent may be a norepinephrine reuptake inhibitors (SNRI). SNRIs include, but are not limited to, duloxetine (CYMBALTA®), desvenlafaxine (PRISTIQ®), levomilnacipran (FETZIMA®), and venlafaxine (EFFEXORXR®).

[0140] The other therapeutic agent can be an anxiolytic agent. Useful anxiolytic agents include, but are not limited to, benzodiazepines, such as alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam; non-benzodiazepine agents, such as buspirone; and tranquilizers, such as barbituates.

[0141] Optionally, the methods of the invention comprise co-administering a DOPA decarboxylase inhibitor. In certain embodiments, decarboxylase enzyme inhibitor is carbidopa, a carbidopa prodrug, benserazide, methylphenidate, or a combination thereof. For example, the decarboxylase enzyme inhibitor is a carbidopa or carbidopa prodrug. For example, the decarboxylase enzyme inhibitor is a benserazide or benserazide prodrug.

[0142] The medicament may comprise a composition according to any one of the following embodiments. The pharmaceutical composition may comprise a composition according to any one of the following embodiments:-A microencapsulated composition comprising a core component comprising a microbial cell (eg, a bacterial cell) capable of producing L-DOPA and colonizing the GI tract (eg, gut) of the subject; and a coating material surrounding the core component.A microbial cell comprising a heterologous hpaB and hpaC nucleotide sequence stably integrated into the genome of the cell.

[0143] Optionally, the microbial cell is a probiotic.

[0144] Optionally, the probiotic is E. colt Nissle 1917.

[0145] Optionally, the microbial cell comprises a heterologous hpaB and hpaC nucleotide sequence.

[0146] Optionally, the hpaB and hpaC nucleotide sequence comprises SEQ ID NO: 1 and 3.

[0147] Optionally, the hpaB and hpaC nucleotide sequence is stably integrated into the genome of the microbial cell.

[0148] Optionally, the hpaB and hpaC nucleotide sequence is contained in a plasmid of the microbial cell.

[0149] Optionally, the hpaB and hpaC nucleotide sequence is operably linked to promoter sequence.

[0150] Optionally, the promoter is a constitutive promoter (eg, a strong, constitutive promoter) or an inducible promoter.

[0151] Optionally, the promoter is a rhamnose inducible promoter.

[0152] Optionally, the core component further comprises an aromatic amino acid- or DOPA -decarboxylase inhibitor.

[0153] Optionally, the DOPA decarboxylase inhibitor is carbidopa or benserazide.

[0154] Optionally, the coating material comprises a polymer.

[0155] Optionally, the coating material comprises alginic acid or an alginate.

[0156] Optionally, the composition further comprises a pharmaceutically acceptable carrier.

[0157] Optionally, the composition is lyophilized.

[0158] Optionally, the microbial cell produces L-DOPA and is capable of colonising the gut of a subject.

[0159] The method may also be a method according to the following embodiments:A method for treating Parkinson’s Disease comprising: administering to a subject in need thereof an effective amount of the microencapsulated composition, the microbial cell, or the lyophilized composition described herein.A method of treating depression and / or anxiety or improving motivational performance comprising: administering to a subject in need thereof an effective amount of the microencapsulated composition, the microbial cell, or the lyophilized composition described herein.

[0160] Optionally, the depression and / or anxiety is associated with Parkinson’s Disease, Parkinsonism, Alzheimer's disease, or other memory disorder.

[0161] The method may also be a method according to the following embodiments: -A method of treating mild cognitive impairment or improving memory and learning comprising: administering to a subject in need thereof an effective amount of the microencapsulated composition, the microbial cell, or the lyophilized composition described herein.

[0162] Optionally, the mild cognitive impairment is associated with Parkinson’s Disease or Parkinsonism.

[0163] Optionally, the mild cognitive impairment is associated with Alzheimer's disease or other memory disorder.

[0164] Optionally, said composition is administered orally.

[0165] Optionally, the composition is administered twice daily, daily, or on alternate days.

[0166] Optionally, the subject is a mammal.

[0167] Optionally, the mammal is a human.Herein: -

[0168] Each microbial cell may comprise a heterologous hpaB and hpaC nucleotide sequence stably integrated into the genome of the cell.

[0169] Each microbial cell may produce L-DOPA and is capable of colonizing the gut of a subject.

[0170] Each microbial cell may be a probiotic, optionally wherein said probiotic is E. coli Nissle 1917.

[0171] The hpaB and hpaC nucleotide sequence is operably linked to a promoter sequence, which may be a constitutive promoter or an inducible promoter (eg, a rhamnose inducible promoter).

[0172] A composition herein may be a microencapsulated composition comprising: a) a core component comprising the microbial cell; andb) a coating material surrounding the core component,c) wherein the core component further comprises an aromatic amino acid- or DOPA -decarboxylase inhibitor.

[0173] The DOPA decarboxylase inhibitor may be carbidopa or benserazide.

[0174] The coating material may comprise a polymer, optionally wherein the coating material comprises alginic acid or an alginate.

[0175] The method herein may be: A method for treating Parkinson’s Disease, depression and / or anxiety, or mild cognitive impairment or improving motivational performance or memory and learning, the method comprising administering to a subject in need thereof an effective amount of the microbial cell or medicament.

[0176] Preferably, said administration herein is oral administration.

[0177] The composition or medicament may be administered twice daily, daily, or on alternate days.

[0178] The subject is preferably a mammal. The subject is more preferably a human.

[0179] Herein the method may treat or reduce the risk of depression, anxiety or mild cognitive impairment is associated with Parkinson’s Disease, Parkinsonism, Alzheimer's disease, or other memory disorder.

[0180] It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine study, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications and all US equivalent patent applications and patents are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Reference is made to the publications mentioned herein and equivalent publications by the US Patent and Trademark Office (USPTO) or WIPO, the disclosures of which are incorporated herein by reference for providing disclosure that may be used in the present invention and / or to provide one or more features (e.g. of a vector) that may be included in one or more claims herein.

[0181] Any part of this disclosure may be read in combination with any other part of the disclosure, unless otherwise apparent from the context.

[0182] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and / or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

[0183] The present invention is described in more detail in the following non-limiting Examples.EXAMPLESExecutive summary

[0184] L-dihydroxyphenylalanine (L-DOPA) is a precursor to the neurotransmitter dopamine and used as a drug in the treatment of Parkinson’s Disease. A probiotic E. coli strain was engineered to convert L-tyrosine to L-DOPA. The construct was tested for pharmacokinetics in healthy Wistar rats and for pharmacodynamics in the 6-OHDA disease model (chemically induced Parkinson’s Disease) in Wistar rats. The pharmacokinetic study in rats indicated continuous sustainable availability of L-dopa to the brain, as the dopamine levels in the brain were increased for 24 hours after the last dose and 3-OMD levels were maintained low relative to L-dopa treated animals. The efficacy study of L-dopa produced by the E. coli bacteria (b9375) in the gut showed significant reversing of motor deficits observed in the cylinder and initiation tests with no observed dyskinesia.Objectives

[0185] We aimed to investigate the following objectives.• Development of L-DOPA production and secretion to the growth medium by a probiotic chassis strain• Development of an in-house assay for the quantification of L-DOPA production• Show that production of L-DOPA in gut of rats will result in increased dopamine levels in the brain and secondarily show that the produced L-DOPA results in more constant levels supplied to the brain over 24 hours• Show that L-DOPA produced in the gut of rats results in a decrease in Parkinsonian symptoms from the 6-OHDA induced damage to the brainMaterials and methodsBacterial strain and growth conditions for plasmid cloning

[0186] Escherichia coli strain NEB® Turbo from New England Biolabs (Ipswich, MA, USA) was used for cloning of plasmids. This strain is registered as b3127. Cultures were routinely grown at 37 °C in Luria-Bertani (LB) broth at 250 RPM or on solid media LB-agar plates made with 1.5% (w / v) agar. For plasmid selection, the medium was supplemented with 50 pg ml1Kanamycin (Km) or with 100 pg ml1spectinomycin (Sp).Plasmid and strain construction

[0187] Plasmids were constructed by In-Fusion cloning (Takara Bio, Mountain View, CA, USA) using PCR generated fragments. The strains and plasmids used in this study are listed in Appendix A. Engineering of chromosomal genes was performed by recombineering using PCR generated DNA (Datsenko and Wanner, 2000).

[0188] Key elements of the constructed L-DOPA producing cells are shown in Figure 1.

[0189] An E. coli (internal number b7951) was used as a starting strain. First, the open reading frame encoding the tyrosine repressor (TyrR) was deleted, resulting in strain b8525. This serves two purposes, it derepresses transporters that are responsible for tyrosine uptake from the environment (TyrP, AroP), and derepresses genes responsible for tyrosine synthesis in the cell (tyrA, tyrB). The hpaBC operon encoding 4-hydroxyphenylacetate 3 -hydroxylase, the enzyme catalysing the tyrosine L-DOPA conversion (Prieto & Garcia 1994), was PCR amplified from E. coli strain bl466. Eight different constructs were created that expressed the hpaBC operon (Table 1). These constructs differed in the promoters expressing the hpaBC operon, the presence of the tyrR deletion, and whether the hpaBC operon was carried on the chromosome (at uspG) or on a plasmid (pl5A).Table 1. Characteristics of the HpaBC expressing strains. The mid strength promoter (Pm) had a TAGACA -35 box, while the strong promoter (Ps) had the consensus TTGACA -35 boxStrain tyrR deletion hpaBC location hpaBC promoterb8542 no plasmid Mid strengthb8543 no plasmid Strongb8544 yes plasmid Mid strengthb8545 yes plasmid Strongb8589 no chromosome Mid strengthb8590 no chromosome Strongb8591 yes chromosome Mid strengthb8592 yes chromosome Strong

[0190] The strain used in the animal studies (b9375) was constructed by introducing a mutation conferring streptomycin resistance in b8525 and transforming the resulting strain (b9226) with a pSYM12-based plasmid carrying the strong promoter (Ps)- hpaBC unit (p3268).Protein purification

[0191] NEB Turbo cells carrying the p3139 plasmid were grown in LB supplemented with Km, MgSO4, glucose, and Sodium phosphate buffer (pH 8). When cells reached stationary phase, the culture was centrifuged, and the pellet was frozen at -80 °C. Cells were resuspended in B-PER™ Complete Bacterial Protein Extraction Reagent (Thermo Fisher Scientific) on ice, and Lysozyme was added for better cell lysis. After 30 min, an equal volume of wash buffer was added (Wash buffer: for 50 ml add 1 ml 5M NaCl, 2.55 ml 0.5M NaH2PO4, and 2.45 ml 0.5M Na2HPO4). After 20 min, the lysate was centrifuged at 15000g for 30 min at 4 °C. The cleared supernatant was transferred to a new tube and Ni-NTA agarose (Qiagen) was added, followed by incubation for 1 h on a rocker in the cold room. The mixture was loaded on a Poly prep column (Bio-Rad). The matrix was washed with 15 volumes of wash buffer, and then with 2 volumes of Elution buffer (for 10 ml, add 200 pl 5M NaCl, 0.51 ml 0.5M NaH2PO4, and 0.49 ml 0.5M Na2HPO4, 5 ml glycerol, and 20 mM Imidazole).

[0192] Then proteins were eluted with 5 volumes of Elution buffer with 200 mM Imidazole. Fractions were collected in separate tubes and tested for activity.

[0193] Proteins were stored at -20 °C.In vitro colorimetric L-DOPA assay

[0194] In the presence of DOPA 4, 5, -dioxygenase, L-DOPA is converted to a yellow pigment that can be quantified using a spectrophotometer (Chou et al, 2019). The gene encoding DOPA 4, 5-dioxygenase (DOD) from Mirabilis jalapa (Sasaki et al, 2009) was cloned into a low copy vector with a C-terminal His-tag for protein purification (p3139). The gene was transcribed from a strong constitutive promoter. Development of a strong yellow color was observed when cells carrying p3139 were incubated with L-DOPA, verifying the functionality of the expressed His-tagged protein. The DOD protein was purified by a single step affinity chromatography as described in 3.3.Functionality of the purified protein was verified in the presence of L-DOPA in M9 mediumsupplemented with 10 mM ascorbic acid and with trace elements or FeSC Intensity of the yellow color obtained can be quantified using a spectrophotometer by determining the absorbance at 435 nm.Mass spectrometry

[0195] Cultures were grown overnight at 37 °C in M90.4% glucose supplemented with 1 mM tyrosine, casaminoacids, thiamine and trace-elements. Samples of supernatant were harvested by centrifugation for 10 min at 4500g, followed by filtration through 0.2 pm PES filters. Samples were stored at -20°C. The samples were analysed by LC-MS with a partner in Germany (A&M Labor).L-DOPA production and pharmacokinetics in rats

[0196] This study was a pharmacokinetics (PK) study and was performed in 27 healthy male Wistar rats divided into 9 groups (n=3). The animals were group housed in their respective groups throughout the study. One group of animals (group 1) was sacrificed to determine baseline levels of L-DOPA, dopamine, 3-OMD and DOPAC in the blood, brain and feces. The remaining 8 groups were dosed once daily with our strain (b9375) or twice daily with L-DOPA, both in combination with benserazide:

[0197] Groups 2-5 was dosed perorally once daily with our strain (b9375), and was given benserazide as a subcutaneous infusion via osmotic pump implanted, starting 30 minutes before first peroral dose of strain (8 mg / kg / day at a rate of 10 ul / h). On the day of first dose, a bolus of 12.5 mg / kg benserazide was given SC

[0198] Groups 6-9 were dosed SC twice daily with 10 mg / kg L-DOPA SC and 12.5 mg / kg benserazide SC (4 hours between each dose)

[0199] On day 1 blood samples were taken at 30 min, 1.5, 3, 4.5, 6, 7.5 and 24 hours after the first dose (PK measurements after acute exposure), dosing was then preformed daily and on day 7 animals were terminated at 4.5, 6, 7.5 or 24 hours after the last dose (PK measurement after long term exposure). At termination blood, brain and feces were collected for quantification of L-DOPA, dopamine, 3-OMD and DOPAC by LC-MS (see figure 2).L-DOPA efficacy in Parkinsonian rats (6-OHDA induced)

[0200] The study was performed in 52 male Wistar rats. The rats were acclimatized and were divided into four groups (n=13). The rats then underwent surgery where groups 2-4 got 6-OHDA injected into their left substantia nigra pars compacta, which results in stereotaxic dopaminergic lesion. The group 1 underwent the same procedure, but with injection of saline. The surgery was performed on day 0 and the animals were then allowed healing until day 6. Starting on day 6 the animals were given streptomycin 1 g / L in the drinking water, available ad libitum for the remaining time of the study. On day 7, all animals went through surgery for implantation of anosmotic pump subcutaneously. The pumps were filled with saline for groups 1-3 and for group 4 with benserazide (7-10 mg / kg continuously). All animals started dosing on day 7:

[0201] Groups 1-2 were dosed twice daily perorally (PO) via gavage of PBS (vehicle) and with supplementary saline SC in correlation with the AM dosing from day 7-14 (all days)

[0202] Group 3 was dosed twice daily with PBS (vehicle) PO and with supplementary saline SC in the AM from day 7-13 and then the last day (day 14) the animals were dosed with 10 mg / kg L-DOPA SC and 12.5 mg / kg benserazide SC 1.5 hours before behavioral tests

[0203] Group 4 was dosed twice daily with 4.8xl09CFU of b9375 PO and supplemented with 12.5 mg / kg benserazide SC in the AM from day 7-14 (all days). On the last day (day 14) the animals underwent behavioral testing approx. 1.5 hours after their last dose

[0204] The behavioral test included the initiation test and the cylinder test. We further collected feces from group 4 (only), followed by transcardiac perfusion with PBS and brain extraction (all groups) at termination. All fecal samples were frozen homogenized in 1 mb PBS with 20% glycerol and shipped to SNIPR for CFU quantification. The brain sampled were prepared for potential staining at a later timepoint and stored. See figure 3 for study overview.ResultsCharacterization of L-DOPA producing strains

[0205] The hpaBC operon present in certain E. coli strains encodes 4-hydroxyphenylacetate 3 -hydroxylase, the enzyme catalysing the tyrosine L-DOPA conversion (Prieto & Garcia 1994). First, the operon was cloned into a pl5A based plasmid or inserted at the uspG gene on the chromosome in two different strains, which differed in the presence of the tyrosine repressor (TyrR). This resulted in eight strains, described in Materials and methods (3.2). The constructed strains were tested for L-DOPA production by a colorimetric assay developed at SNIPR based on previous publication (Chou et al, 2019). L-DOPA in the culture supernatants was also determined by LC-MS (Materials and methods 3.5). Highest L-DOPA production was obtained when the hpaBC operon was cloned into a plasmid and expressed from a strong promoter in a AtyrR strain (Figure 4).

[0206] The best L-DOPA producing strain, b8545, was tested for maintenance of p3150 in the absence of antibiotic selection. Substantial loss of the hpaBC carrying plasmid (p3150) was observed. Therefore, the Vs-hpaBC unit was cloned into the pSYM12 plasmid, which had no stability issues in the absence of selection (p3268). The resulting plasmid was introduced into the streptomycin resistant version of the tyrR strain, b9226. The resulting strain (b9375) contained only p3268 and not the original pSYM12 plasmid. The sequence of the strain was verified by whole genome sequencing. The b9375 strain produced L-DOPA well, and no loss of the p3268 plasmid was observed after five consecutive re-streaking of single colonies on non-selective plates.Pharmacokinetics in healthy male Wistar rats

[0207] The colonization by the b9375 strain in the pharmacokinetic study showed relatively stable levels of CFU in feces of the rats. The feces contained 104- 106CFU / g feces at termination and selecting for the plasmid showed similar CFU’s indicating limited plasmid loss and thereby supports stability of the plasmid (see figure 5). We further confirmed that the groups 6-9 were not contaminated by our bacterial strain.

[0208] The pharmacokinetic samples collected consisted of blood samples on day 1, and further blood and brain samples on day 7 at termination.

[0209] The baseline level of L-DOPA is found at levels of 1.36 ng / mL and the E. coli-dosed animals (b9375) showed a slight decrease at 6 hours, but otherwise remained stable throughout the 24 hours at 0.9-1.76 ng / mL in blood. In the L-DOPA treated animals a spike was observed at 1.5 hours after dose with rapid decrease by 3 hours and another spike at 6 hours, slowly decreasing to baseline levels by 24 hours. The dopamine baseline level was found at levels of 1.51 ng / mL in blood and the E. coli dosed animals showed dopamine levels constantly 0.5-2 ng / mL higher than the L-DOPA dosed animals with a peak at 30 min (4.51 ng / mL) and again at 4.5 hours (2.85 ng / mL). The L-DOPA treated animals showed constantly lower levels than E. coli dosed animals with a decreasing level from 30 min - 6 hours and then going back to baseline by 24 hours. The 3-OMD metabolite is found when L-DOPA levels are high and the metabolism shifts from dopaminergic utilization to peripheral utilization. The 3-OMD metabolite is unwanted at high levels in the brain, as it indicates overload of L-DOPA. On day 1 there is no detectable level of 3-OMD in the blood in the baseline animals. E. coli producing L-DOPA results in a constant low level with a continuous increase from 30 min to 24 hours, from 16.3 to 352.0 ng / mL. The L-DOPA dosed animals have a much higher 3-OMD concentration than E. coli dosed animals and continuous increase from 30 minutes to 7.5 hours, from 1219 to 7887 ng / mL with a decrease to 2982 ng / mL by 24 hours. The DOPAC metabolite comes from metabolism of dopamine. The baseline level was found at 6.11 ng / mL. The E. coli dosed animals have levels spiking to 8.63 ng / mL at 30 min with a continuous decrease to below baseline at 6 and 7.5 hours post first dose. There’s a slight increase in the blood levels to 1.93 ng / mL at 24 hours (see figure 6).

[0210] The day 1 results showing no increase in L-DOPA blood levels from the E. coli strain (b9375) could indicate quick conversion into dopamine from L-DOPA. This could be further supported by the slightly higher levels of blood dopamine relative to the L-DOPA dosed group.Further supporting L-DOPA production by E. coli (b9375) is the increase of 3-OMD in the blood over 24 hours. We did not expect the E. coli to produce immediately after the first dose, hence these results were to be expected.

[0211] On day 7, being the last day of dosing, the blood sampling was repeated at the same schedule as day 1 after the last dose and would show blood levels after daily dosing for 7 days(chronic dosing). The E. coli dosed animals showed L-DOPA levels in blood fluctuating between highs at 1.5 hours and 6 hours, and lows at 3 and 24 hours, with levels between 1.84-3.34 ng / mL. The L-DOPA dosed animals continuous increase from baseline levels at 30 min to highest concentration at 4.33 ng / mL at 7.5 hours post dose, with decreasing levels by 24 hours (2.65 ng / mL). Looking at the dopamine levels, the E. coli dosed animals showed continuous levels fluctuating around 2.50 ng / mL. There is a decrease to a low at 3 hours at 1.53 ng / mL dopamine, followed by a peak at 4.5 hours at 3.80 ng / mL ending at 24 hours with 2.38 ng / mL dopamine in blood. The L-DOPA dosed animals are showing stable levels of dopamine at around 1.00-1.35 ng / mL at all measured timepoints, similar to baseline levels at 1.51 ng / mL. The 3-0 MD levels in the E. coli dosed animals showed relatively constant levels throughout the 24 hours (446.0-769.0 ng / mL). Interestingly the L-DOPA treated animals had much higher levels of 3-OMD in the blood after the last dose on day 7. The L-DOPA treated animals had a continuous increase from 30 minutes to 7.5 hours, with 7835 to 14143 ng / mL 3-OMD in blood followed by a decrease to 4259 ng / mL by 24 hours. The DOPAC levels in blood after the last dose on day 7, showed that the E. coli dosed animals had mean levels decreasing to below baseline by 3 hours, with an increase to 4.73 ng / mL by 4.5 hours followed by another decrease to 1.45 ng / mL at 6 hours followed by increasing to 5.46 ng / mL at 24 hours. The L-DOPA treated animals had more stable fluctuations between 2.52 ng / mL at lowest at 30 min to 4.73 ng / mL at 4.5 hours. The patterns are the same as with E. coli, but less intense in fluctuations (see figure 7).

[0212] Overall, the results in the blood after the last dose on day 7 showed indication of L-DOPA production, although lower than L-DOPA treated animals. The continuously higher levels of dopamine in blood relative to the L-DOPA strain however indicates production from our E. coli strain (b9375). The stable level of 3-OMD over 24 hours for the E. coli dosed animals further supports the production of L-DOPA at a stable level. Whereas the 3-OMD at high levels in L-DOPA dosed animals indicates a potential excess of L-DOPA which could be putting animals at risk of dyskinesia and are undesirable. In this case we are seeing an expected increase in 3-OMD which can result in toxic side effects in the L-DOPA treated animals, whereas the lower levels in E. coli dosed animals is a benefit, as it reduces likelihood of side effects. The E. coli and L-DOPA dosed animals showed no indication of dopamine metabolism when comparing DOPAC levels in blood with baseline levels.

[0213] We further collected the brains after termination at 4.5 to 24 hours after the last dose performed on day 7. The results showed that baseline animals that were naive (had never been dosed) and that the E. coli dosed animals did not have L-DOPA levels in the brain tissue above the limit of detection at any of the timepoints. The L-DOPA dosed animals had a high level of L-DOPA at 158 ng / mL in the brain at 4.5 hours after the last dose, with a sharp decrease to 32.6 ng / mL by 6 hours and further decreasing to 16.4 ng / mL by 7.5 hours, with no detection above the limit of detection at 24 hours. The dopamine levels in the brain were found to be below the limit of detection for naive animals. The E. coli dosed animals had levels fluctuating between 22 ng / mL (low at 4.5 hours) and 65.5 ng / mL (high at 6 hours) over the course of 24 hours after the last dose. The L-DOPAdosed animals had the highest level of dopamine at 79.9 ng / mL in the brain at 4.5 hours after the last dose and remaining at approximately the same level at 6 hours followed by a decrease to 28.6 ng / mL at 7.5 hours. There was no dopamine found in the brain at 24 hours after the last dose (L0D=5ng / mL). The 3-OMD metabolite was below the limit of detection (10 ng / mL) in naive animals. The E. coli dosed animals had relatively constant levels around 17-25 ng / mL at the timepoints 4.5 to 24 hours after the last dose. The L-DOPA animals had 589 ng / mL at 4.5 hours after the last dose, which further increased to 634 ng / mL by 6 hours slowly decreasing by 7.5 hours and having decreased markedly to 195 ng / mL by 24 hours. The 3-OMD levels indicated a very high level of L-DOPA having forced the metabolism of L-DOPA into 3-OMD, rather than remaining as dopaminergic metabolism. Lastly, the DOPAC levels in the brain were investigated and showed levels below the limit of detection in naive animals. The E. coli dosed animals had DOPAC levels in the brain fluctuating between 23.6 ng / mL and 189.4 ng / mL with 4.5 hours being the lowest and 7.5 hours after the last dose being the highest. The L-DOPA dosed animals had 71 ng / mL at 4.5 hours after the last dose increasing to 146 by 6 hours post dose, but values were found below LOD from 7.5 hours and onwards (see figure 8).

[0214] Overall the results on the brain concentration showed no detectable L-DOPA in the brain of E. coli dosed animals which we believe indicates surprisingly efficient conversion of L-DOPA into dopamine, which was supported by the data on dopamine in the brain. Dopamine levels in the E. coli dosed animals were approx. 28% of the L-DOPA dosed animals at 4.5 hours post dose, with a surprising increase to 83% of the L-DOPA dosed animals at 6 hours post last dose. Moreover, at 7.5 and 24 hours after the last dose the animals dosed with E. coli had detectable and stable levels at approx. 42 ng / mL whereas the L-DOPA dosed animals had levels below LOD. The dopamine levels were expected to drop below LOD in the L-DOPA dosed animals due to the short halflife of L-DOPA. We have here surprisingly shown that we have continuous and stable dopamine levels in the brain of E. coli GI tract-dosed animals. The 3-OMD concentrations in the brain of E. coli dosed animals advantageously remained low at 17.3-24.6 ng / mL, whereas the L-DOPA dosed animals had levels at 195-634 ng / mL. The 3-OMD levels are interesting as the higher levels in the L-DOPA dosed animals could indicate an undesirable excess amount of L-DOPA entering the brain, which may result in toxic effects on the brain over time, including dyskinesia / akinesia and further may be leading to a reduced uptake of L-DOPA in the brain over time. With the E. coli dosed animals showing 3-OMD levels at only 0.3-9.4% of the L-DOPA animals there is a potential for reduced neurotoxicity and a maintained uptake of L-DOPA over longer time which we hypothesise would be beneficial. Further advantageously supporting a constant influx of L-DOPA and hereby a constant supply of dopamine in the E. coli dosed animals is the level of DOPAC which is a metabolite of dopamine found in the brain 24 hours after the last dose. The L-DOPA animals have no detectable DOPAC at 7.5 hours post dose and onwards, indicating no further L-DOPA supply and dopamine metabolism which is likely to result in a dopamine trough and worsened dyskinesia or akenesia in a disease setting.Efficacy in 6-OHDA induced male Wistar rats

[0215] The 6-OHDA disease model in rats was completed with no dose related adverse findings after 1 week of peroral dosing with E. coli (b9375) twice daily for 7 days. On the day of termination fecal samples were collected from all animals in group 4 (dosed with E. coli, b9375) to quantify CFU numbers in feces. The fecal samples were plated to select for the bacteria and also the plasmid to confirm the stability. The results showed that the bacteria were found at approx. 105- 109CFU / g feces, however due to a mistake the numbers may vary as the fecal samples had not been weighed and an expected fecal weight was calculated based on the weight of feces from the rats in the previous study. The CFU quantification can nevertheless still be used to confirm that the bacteria were found in feces, and as the same sample was used for both selection markers, it was possible to confirm that loss of plasmid is very limited after 7 days of dosing in rats on streptomycin (see figure 9).

[0216] The standard behavioral tests performed included the initiation test and the cylinder test. The initiation test tested the time of initiation of movement of the affected right paw, when movement of the 3 other legs were restricted. The test looked at the time from 1-90 seconds and longer than 90 secons was registered as 90 seconds. In the initiation test it was seen that the healthy control animals had a mean score of 1.69 seconds, with 9 / 12 animals receiving the lowest score of 1 second. The disease control had a mean score of 49.26 seconds with 1 animal scoring 1 second, and one animal receiving the highest score of 90 seconds. Animals with scores of 1 or close to 1 second would need histological brain stains to confirm they had infact had a successful 6-OHDA induction. The treatment control, which received L-DOPA only once (on day of termination approx. 1.5 hours before testing) showed a mean score of 15.06 seconds with 1 animal scoring 1 seconds and the highest score being 34.83 seconds, indicating an improvement, but statistically only different from the healthy control (p<0.05, Kruskal-Wallis followed by Dunnett’s test). The E. coli dosed (b9375) animals showed a further reduction in initiation time relative to treatment control, as the mean went slightly down to 34.03 seconds, with 5 of the animals at the lowest score of 1 second, and the highest measured as 31.83 seconds. The measurement of E. coli treated animals showed statistical difference from the disease control (p<0.05, Kruskal -Wallis followed by Dunnett’s test), but there was no statistical difference from the healthy control group (see figure 10).

[0217] The cylinder test was performed in the rats that were placed in an upright cylinder and the contact time of the right paw, left paw and double contact time was registered as a percentage during the test lasting 7 minutes in total. The results showed that the healthy control used its right and left paw similarly at approx. 28% of the time, and that the double contact time was approx. 44% of the time. The disease control showed as expected a decrease in the contact time of the right paw (approx.10%) and an increase of the contact time of the compensating left paw (approx. 62%), whereas the double contact time went slightly down to approx. 28% of the time. The change in contact time for allthree parameters were significant for healthy versus disease control animals. The L-dopa dosed animals, treatment control, showed that the contact time of the right paw was restored with approx.28% contact time (p<0.01, relative to disease control), with the compensating left paw being used significantly less (p<0.05) relative to the disease control with a total of approx. 39% of the contact time. The double contact time was approx. 33% which was not different from neither the healthy control nor the disease control. The E. coli dosed (b9375) animals showed some restoration in the use of the right paw, as the contact time increased to approx. 18% which resulted in statistical difference from both the healthy control (p<0.05) and the disease controls (p<0.05). The use of the compensating left paw was significantly reduced at approx. 44% which was statistically different from the disease controls (p<0.05), but not from the healthy control. The double contact time was found to be improved at approx. 38% of the contact time, but not statistically different from neither the disease control nor the healthy control (see figure 11). All statistics were performed using Kruskal-Wallis followed by Steel-Dwass multiple comparison test.

[0218] Overall, the results showed that L-dopa producing E. coli (b9375) dosed to animals twice a day had a modest effect on the use of the right limb, as the treatment improved the contact time significantly relative to the disease control and with no statistical difference from the L-dopa treated animals. However, there was still some statistical difference relative to the healthy control. A statistically significant reduction in the use of the compensatory left forelimb relative to the disease control was shown. Further, no statistical difference between the healthy control and the L-dopa treated animals indicates gut-produced L-dopa improves symptoms as it reduces the reliance on the unaffected forelimb. Dosing of E. coli (b9375) further showed an increase in double limb contacts compared to the disease control suggesting an improvement in motor coordination due to the gut-produced L-dopa. The data in this test is not as strong as in the initiation test, but there are clear statistical improvements in the use of both the right and left fore limbs in this test with no statistical difference from the L-dopa dosed animals.Conclusions

[0219] We have successfully engineered an E. coli and administered to produce L-DOPA in the GI tract resulting in constant availability of dopamine to the brain and with reduced risk of neurotoxicity and dyskinesia relative to L-DOPA dosed animals. The following surprising activities were achieved with dosing of engineered bacteria to the GI tract: - • elevating brain dopamine that is useful for treating or preventing PD;• elevating and stabilizing brain dopamine level more than 2-fold in the brain in the period of 24 hours immediately post administration;• elevating brain dopamine whilst reducing dopamine fluctuation for more than 5 consecutive hours in the 24 hours;• elevating and stabilizing brain DOPAC more than 2-fold in the brain in the 24 hours;• reducing the reduced risk of 3-OMD-mediated toxicity.

[0220] With the engineered bacteria we further showed efficacy in reducing the initiation time of the affected right paw - this seems to be even superior to L-DOPA treatment (treatment control). The improvement on the spontaneous use of the affected (right) paw in the cylinder test was less pronounced, but showed an improvement in the use of the left limb and double contact relative to the disease control. The strain was also effective in reversing the motor deficits observed in the cylinder test. Lastly, 7 days of dosing with L-dopa producing E. coli did not show apparent signs of dyskinesia during the experiment.References1. Datsenko KA, Wanner BL. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Set USA. 97(12), 6640-5.2. Kovach ME, et al. (1995). Four new derivatives of the broad-host-range cloning vector pBBRIMCS, carrying different antibiotic-resistance cassettes. Gene. 166:175-6. doi:10.1016 / 0378-1119(95)00584-13. Prieto, M. A., & Garcia, J. L. (1994). Molecular characterization of 4-hydroxyphenylacetate 3 -hydroxylase of Escherichia coli. A two-protein component enzyme. The Journal of biological chemistry, 269(36), 22823-22829.4. Chou, Y. C., Shih, C. I., Chiang, C. C., Hsu, C. H., & Yeh, Y. C. (2019). Reagent-free DOPA -dioxygenase colorimetric biosensor for selective detection of L-DOPA. Sensors and Actuators B: Chemical, 297, 126717.5. Sasaki, N., Abe, Y ., Goda, Y ., Adachi, T., Kasahara, K., & Ozeki, Y. (2009). Detection of DOPA 4, 5 -dioxygenase (DOD) activity using recombinant protein prepared from Escherichia coli cells harboring cDNA encoding DOD from Mirabilis jalapa. Plant and Cell Physiology, 50(5), 1012-1016.AppendicesTable 2: Strains used in this studyStrain Features Referenceb3127 NEB Turbo New England Biolabs b7951 E. coli chassis strain SNIPR Biomeb8525 b7951 AtyrR SNIPR Biomeb9226 b8525 strR SNIPR Biomebl466 HpaBC+ E. coli strain SNIPR Biomeb8589 b7951 Pm-hpaBC SNIPR Biomeb8590 b8525 Ps-hpaBC SNIPR Biomeb8591 b7951 Pm-hpaBC SNIPR Biomeb8592 b8525 Ps-hpaBC SNIPR Biomeb8542 b7951 p3148 SNIPR Biomeb8543 b7951 p3150 SNIPR Biomeb8544 b8525 p3148 SNIPR Biomeb8545 b8525 p3150 SNIPR Biomeb9375 b9226 p3268 SNIPR BiomeTable 3: Plasmids used in this study

[0221] Plasmid

[0222] Features

[0223] Reference

[0224] pBBR-

[0225] Low copy vector

[0226] Kovach et al, MCS2 1995

[0227] p3139

[0228] pBBR-MCS2 -

[0229] SNIPR Biome DOD-His

[0230] p3148

[0231] CloDF13 with Pm-

[0232] SNIPR Biome hpaBC

[0233] p3150

[0234] CloDF13 with Ps-

[0235] SNIPR Biome hpaBC

[0236] p3268

[0237] pSYM12 with Ps-

[0238] SNIPR Biome hpaBCTable 4: DNA and protein sequences

[0239] hpaB DNA sequence (SEQ ID NO: 1) atgaaaccagaagatttccgcgccagtacccaacgtccgttcaccggggaagagtatctgaaaagcctgcaggatggtcgcgagatctatatctat ggcgagcgagtgaaagacgtcaccactcatccggcatttcgtaatgcggcagcgtctgttgcccagctgtacgacgcactgcacaaaccggagat gcaggactctctgtgctggaacaccgacaccggcagcggcggctatacccataaattcttccgcgtggcgaaaagtgccgacgacctgcgccag caacgcgacgccatcgctgagtggtcacgcctgagctatggctggatgggccgtaccccagactacaaagctgctttcggttgcgcactgggcgc gaatccgggcttttacggtcagttcgagcagaacgcccgtaactggtacacccgtattcaggaaactggcctctactttaaccacgcgattgttaacc caccgatcgatcgtcatttgccgaccgataaagtaaaagacgtttacatcaagctggaaaaagagactgacgccgggattatcgtcagcggtgcgaaagtggttgccaccaactcggcgctgactcactacaacatgattggcttcggctcggcacaagtaatgggcgaaaacccggacttcgcactgatgtt cgttgcgccaatggatgccgatggcgtcaaattaatctcccgcgcctcttatgagatggtcgcgggtgctaccggctcaccgtatgactacccgctct ccagccgcttcgatgagaacgatgcgattctggtgatggataacgtgctgatcccatgggaaaacgtgctgatctaccgcgattttgatcgctgccgt cgctggacgatggaaggcggtttcgcccgtatgtatccgctgcaagcctgtgtgcgcctggcagtgaaactcgacttcattacggcactgctgaaa aaatcactcgaatgtaccggcaccctggagttccgtggtgtgcaggccgatctcggtgaagtggtggcgtggcgcaacaccttctgggcattgagt gactcgatgtgttctgaagcgacgccgtgggtcaacggggcttatttaccggatcatgccgcactgcaaacctatcgcgtactggcaccaatggcct acgcgaagatcaaaaacattatcgaacgcaacgttaccagtggcctgatctatctcccttccagtgcccgtgacctgaacaatccgcagatcgacca gtatctggcgaagtatgtgcgcggttcgaacggtatggatcacgtccagcgcatcaagatcctcaaactgatgtgggatgccattggcagcgagttt ggtggtcgtcacgaactgtatgaaatcaactactccggtagccaggatgagattcgcctgcagtgtctgcgccaggcacaaagctccggcaatatg gacaagatgatggcgatggttgatcgctgcctgtcggaatacgaccagaacggctggactgtgccgcacctgcacaacaacgacgatatcaacat gctggataagctgctgaaataa

[0240] HpaB protein amino acid sequence (SEQ ID NO: 2) MKPEDFRASTQRPFTGEEYLKSLQDGREIYIYGERVKDVTTHPAFRNAAASVAQLYDALHKP EMQDSLCWNTDTGSGGYTHKFFRVAKSADDLRQQRDAIAEWSRLSYGWMGRTPDYKAAF GCALGANPGFYGQFEQNARNWYTRIQETGLYFNHAIVNPPIDRHLPTDKVKDVYIKLEKETD AGIIVSGAKVVATNSALTHYNMIGFGSAQVMGENPDFALMFVAPMDADGVKLISRASYEMV AGATGSPYDYPLSSRFDENDAILVMDNVLIPWENVLIYRDFDRCRRWTMEGGFARMYPLQA CVRLAVKLDFITALLKKSLECTGTLEFRGVQADLGEVVAWRNTFWALSDSMCSEATPWVNG AYLPDHAALQTYRVLAPMAYAKIKNIIERNVTSGLIYLPSSARDLNNPQIDQYLAKYVRGSN GMDHVQRIKILKLMWDAIGSEFGGRHELYEINYSGSQDEIRLQCLRQAQSSGNMDKMMAM VDRCLSEYDQNGWTVPHLHNNDDINMLDKLLK

[0241] hpaC DNA sequence (SEQ ID NO: 3) atgcaattagatgaacaacgcctgcgctttcgtgacgcaatggccagcctgtcggcagcggtaaatattatcaccaccgagggcgacgccggaca atgcggaattacggcaacggccgtctgctcggtcacggatacaccaccgtcgctgatggtgtgcattaacgccaacagtgcgatgaacccggttttt cagggcaacggtaagttgtgcgtcaacgtcctcaaccatgagcaggaactgatggcacgccacttcgcgggcatgacaggcatggcgatggaag agcgttttagcctctcatgctggcaaaaaggtccgctggcgcagccggtgctgaaaggttcgctggccagtcttgaaggagagatccgcgatgtgc aggcgattggcacacatctggtgtatctggtggagattaaaaacatcatcctcagtgcagaaggtcacggacttatttactttaaacgccgtttccatcc ggtgatgctggaaatggaagctgcgatttaa

[0242] HpaC protein amino acid sequence (SEQ ID NO: 4) MQLDEQRLRFRDAMASLSAAVNIITTEGDAGQCGITATAVCSVTDTPPSLMVCINANSAMNP VFQGNGKLCVNVLNHEQELMARHFAGMTGMAMEERFSLSCWQKGPLAQPVLKGSLASLEG EIRDVQAIGTHLVYLVEIKNIILSAEGHGLIYFKRRFHPVMLEMEAAI

[0243] Sequence of the strong promoter used to express hpaBC from psym 12:atcagcgggtcgtgcgagctgtgacaataatactcggctcgtataatgactggaaggctagcaggaggaatca (SEQ ID NO: 5)

[0244] Sequence / reference for psym 12 :GenBank: KM107848.1 (htps: / / www.ncbi.nlm.nih.gov / nuccore / KM107848)

[0245] Official strain number of NEB turbo / b3127:C2984 (website: htps: / / www.neb.com / en / products / c2984-neb-turbo-competent-e-coli-high-efficiency)Description of parameters investigated in the PK in study in rats

[0246] L-D0PA is our bacterially produced compound. L-DOPA is produced endogenously and is affected by feeding. The peak time in rats is at night, with low fluctuations dependent on circadian rhythm.

[0247] Dopamine is a derivative from L-DOPA by AADC (aromatic L-amino acid decarboxylase), and is our goal compound to increase in the brain. Peak time in rats is at night, follows sympathetic activity with adrenal release.

[0248] 3-OMD is a major metabolite of L-DOPA which is formed by COMT (Catechol- O-Methyltransferase). High levels of 3-OMD indicates high levels of L-DOPA in the tissue investigated, with a shift towards COMT metabolism, whereas low levels of 3-OMD indicates low levels of L-DOPA in tissue investigated, with a shift towards desirable dopaminergic utilization instead of peripheral metabolism. There is no peak time and minimal variation in rats.

[0249] DOPAC is a metabolite of dopamine formed by primarily MAO-A / B pathways in neurons and glial cells. High levels of DOPAC desirably indicate availability of dopamine is high. Low levels of DOPAC indicate availability of dopamine is low. Peak time in rats is at night and usually higher with activity.

Claims

1. CLAIMS:

1. A medicament for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells (eg, bacteria) that are capable of secreting a dopamine precursor that is metabolized to dopamine (optionally wherein the precursor is L-3,4-dihydroxyphenylalanine (L-DOPA)), for use in a method for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

2. The medicament of claim 1, wherein the medicament is for elevating brain dopamine in the subject for treating or preventing the neurological disease or condition or symptom.

3. The medicament of claim 1 or 2, wherein the medicament is for use in a method of elevating and stabilizing brain dopamine level in the subject for treating or preventing the neurological disease, condition or symptom in the subject, optionally wherein the brain dopoamine is elevated at least 2-fold in the brain in a period of at least 24 hours, wherein said period is immediately post administration of the medicament.

4. The medicament of any preceding claim, wherein the medicament is for use in a method of maintaining elevated brain dopamine in the subject whilst reducing the risk of dopamine fluctuation (optionally for at least 5 consecutive hours in a period of 24 hours, wherein said period is immediately post administration of the medicament) for treating or preventing the neurological disease, condition or symptom in the subject.

5. The medicament of any preceding claim, wherein the medicament is for use in a method for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level and treating or preventing the neurological disease, condition or symptom in the subject, optionally wherein the DOPAC level is elevated at least 2-fold in the brain in a period of 24 hours, wherein said period is immediately post administration of the medicament.

6. The medicament of any preceding claim, wherein the medicament is for reducing the reduced risk of 3-O-methyldopa (3-0MD)-mediated toxicity in the subject and treating or preventing the neurological disease, condition or symptom.

7. The medicament of any preceding claim, wherein the method is fora) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain L-DOPA over said period;b) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain 3-OMD over said period;c) treating or preventing a neurological disease, condition or symptom whilst maintaining a low level of brain L-DOPA over said period;d) lowering the risk of an L-DOPA brain treatment side effect in the subject;e) lowering the risk of a brain dopamine fluctuation side effect in the subject;f) lowering the risk of dyskinesia, akinesia and / or a neurotoxicity symptom in the subject; g) reducing progression of dyskinesia, akinesia and / or a neurotoxicity symptom in the subject;h) improving motor function in the subject;i) reducing deterioration of motor function in the subject;j) lowering the risk of 3-OMD driven reduced L-DOPA uptake into the brain;k) lowering the risk of metabolism in the brain of L-DOPA to 3-OMD;l) treatingor reducing the risk of addiction behaviour in a subject that has previously received L-DOPA treatment (eg, L-DOPA SOC); orm) treating or preventing a neurological disease or condition whilst reducing one or more side effects (eg, dyskinesia) compared to administration of oral administration of L-DOPA per se.

8. The medicament of any preceding claim, wherein the method comprises increasing (optionally producing to increase) a gut DOPA decarboxylase inhibitor (eg, carbidopa or benzeraside) in the subject.

9. The medicament of any preceding claim, wherein the method comprises administering the medicament and a DOPA decarboxylase inhibitor to the gut of the subject.

10. The medicament of any preceding claim, wherein the method comprises administering the medicament and a MAO-B (monoamine oxidase B) or COMT (catechol-O-methyltransferase) inhibitor to the gut of the subject.

11. The medicament of any preceding claim, wherein the method comprises (i) administering the medicament to the gut of the subject on a first day (Di) and (ii) in a window starting with Di and ending on the sixth day (De) thereafter administering a DOPA decarboxylase inhibitor to the GI tract of the subject on at least 3 days.

12. The medicament of claim 11, wherein (i) the method comprises administering said inhibitor on at least 4, 5 or 6 days in said window; or on each day in said window; or continuously for at least453, 4, 5, 6 or 7 consecutive days in said window; or continuously for the 7 consecutive days of said window; or (ii) the inhibitor is administered at 0.5mg / kg or more per day (optionally from 0.5 to 15 mg / kg) of administration of the inhibitor or at 0.5mg / kg or more per day (optionally from 0.5 to 15 mg / kg) each day of said window.

13. The medicament of any preceding claim, wherein the method comprises administering tyrosine to the subject.

14. The medicament of any preceding claim, wherein the microbial cells have been engineered to de-repress one or more tyrosine importers and / or importers of a precursor that is metabolized to tyrosine.

15. The medicament of any preceding claim, wherein the method is for reducing the risk in the subject ofa) impaired locomotor activity (eg, vestibulomotor function or motor coordination); b) neurodegeneration (eg, dopaminergic neurodegeneration in the mid-brain);c) intraneuronal inclusions;d) loss of dopaminergic neurons (eg, in the in the substantia nigra);e) olfactory dysfunction;f) spatial learning deficit;g) depression;h) anxiety;i) a neuropsychiatric disorder;j) developing one or more Parkinson’s Disease neurological symptom; ork) progression of one or more symptoms (eg, neurological symptoms) of Parkinson’s Disease.

16. The medicament of any preceding claim, wherein the method is for reducing the risk in the subject of dyskinesia, optionally for reducing the risk of 3-O-methyldopa (3-OMD)-mediated dyskinesia in the subject.

17. The medicament of any preceding claim, wherein the condition is a neurodegenerative condition, optionally Parkinson’s Disease or Alzheimer’s Disease.

18. The medicament of any preceding claim, wherein the microbial cells are capable of colonizing the gut (eg, the small intestine and / or colon) of the subject.4619. The medicament of any preceding claim, wherein the microbial cells comprise heterologous hpaBC genes.

20. The medicament of any preceding claim, wherein the microbial cells are devoid of a functional tyrR gene, optionally wherein (i) the microbial cells comprise a knock-out of tyrR; or (ii) the microbial cells comprise a knock-out of tyrR and knock-in of hpaBC genes.

21. The medicament of any preceding claim, wherein the microbial cells comprise hpaBC genes that are under the control of a strong promoter.

22. The medicament of any preceding claim, wherein in the method at least one dose of the medicament is orally administered to the subject, optionally daily or weekly.

23. The medicament of any claim 22, wherein each dose comprises at least 107CFU of said microbial cells.

24. The medicament of any preceding claim, wherein in the method at least one dose of a decarboxylase inhibitor (eg, carbidopa or benzeraside) is administered to the subject (eg, daily or weekly), optionally wherein the medicament and inhibitor are co-administered to the subject.

25. A medicament according to claim 1 for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain dopamine for treating or preventing a neurological disease or condition or a symptom thereof in the subject, wherein the brain dopoamine is elevated at least 2-fold in the brain in a period of at least 24 hours, wherein said period is immediately post administration of the medicament.

26. A medicament according to claim 1 for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for maintaining elevated brain dopamine in the subject whilst reducing the risk of dopamine fluctuation for at least 5 consecutive hours in a period of 24 hours, wherein said period is immediately post administration of the medicament, for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

27. A medicament according to claim 1 for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating and stabilizing brain 3,4-dihydroxyphenylacetic acid (DOPAC) level and treating or preventing a neurological disease or condition or a symptom thereof in the subject, wherein the DOPAC is elevated at least 2-fold in the brain in a period of 24 hours, wherein said period is immediately post administration of the medicament.

28. A medicament according to claim 1 for administration to the gastrointestinal tract (GI tract) of a subject, wherein the medicament comprises engineered microbial cells that are capable of secreting L-DOPA or a precursor thereof, for use in a method for elevating brain dopamine and reducing the reduced risk of 3-O-methyldopa (3-0MD)-mediated toxicity in the subject for treating or preventing a neurological disease or condition or a symptom thereof in the subject.

29. A pharmaceutical composition comprising engineered microbial cells as defined in any preceding claim, and a pharmaceutically acceptable excipient or carrier.

30. The pharmaceutical composition of claim 29, which is formulated for oral or rectal administration, preferably oral administration, for example comprised by a capsule or coated tablet, a gel for retention in the GI tract (eg, in the intestine), or a suppository for rectal administration.

31. The pharmaceutical composition of claim 29 or 30, which is a lyophilised formulation or is an encapsulated formulation to be released in the gut of a subject, for example in the small intestine or large intestine of a subject.

32. The pharmaceutical composition of claim 31, which is formulated as an enteric late release capsule.

33. The pharmaceutical composition according to any one of claims 29 to 32, wherein the composition comprises (or comprises approximately) lx 107colony forming units (CFU) / gram of the engineered microbial cells.

34. A method for treating or preventing a neurological disease or condition in a subject, the method comprising administering to the GI tract of the subject a medicament or composition according to any preceding claim.

35. The method of claim 34, wherein the method is as recited in any of claims 1-28.

36. A medicament, composition, engineered microbial cells (eg, bacteria) or method as herein described.